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Abstract
Histone deacetylases (HDAC) and matrix metalloproteinases (MMPs) are
metalloenzymes with catalytic Zn2+ ions that are over-expressed in a number of physiological
conditions; thus, inhibiting these enzymes is an important therapeutic approach for many
diseases. An HDAC structural mimetic was developed using a ligand, bis(2-picolyl)amine
(BPA), that strongly chelated Zn2+ and did not dissociate upon addition of an HDAC inhibitor.
Using Isothermal Titration Calorimetry (ITC) it was found that BPA binds Zn2+ very strongly in a
1:1 stoichiometric ratio. Two known zinc-binding HDAC inhibitors, acetohydroxamic acid and
8-hydroxyquinoline, were used to study the HDAC inhibitor interaction with the BPA-Zn2+
complex using ITC. Results confirmed that the BPA did not dissociate from Zn2+ upon titration
of either of the inhibitors and that the BPA- Zn2+ complex left adequate coordination sites on
Zn2+ such that a BPA-Zn2+-Inhibitor complex was formed. The interactions of three members of
the tetracycline family antibiotics with Zn2+ and Ca2+ were also studied using ITC and/or UV-Vis
spectroscopy. Though widely known for their antimicrobial properties, the tetracyclines have
been reported to inhibit MMPs by binding structural Ca2+ and Zn2+ ions. Chemically modified
tetracyclines have been developed that lack the antimicrobial activity but still inhibit MMPs to
prevent further antibacterial resistance development. ITC studies of the interaction of Zn2+ with
tetracycline, minocycline, and tigecycline were performed at pH 6.80 and at pH 7.50. Of the
three antibiotics, minocycline was found to have the highest affinity for Zn2+, two- and fourtimes as high as for tigecycline and tetracycline, respectively. The composition of the
tetracycline complex with Zn2+ was pH-dependent while that of minocycline and tigecycline with
Zn2+ were not. Previous work in the Jin lab investigated the interaction of tetracycline,
minocycline, and tigecycline with Ca2+ at pH 6.80 and at pH 7.50 using ITC. The stoichiometries
for the interactions of tetracycline, minocycline and tigecycline with Zn2+ and Ca2+ obtained
using ITC were confirmed using UV-Vis spectroscopy analyzed with Job’s method. Knowledge
about active site metal-ion contribution to HDAC inhibitor binding energetics and about the
energetics of tetracycline binding to structural MMP metal ions will enhance the design of
HDAC and MMP inhibitors.
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Chapter 1. Introduction
1.1 Introduction to Zinc Metalloenzymes
Although metals only account for 3% by mass of the human body, they play a
disproportionately integral role in the body’s function.1 Among the physiological metal ions are
the first row transition metals, which are present in the center of the active sites – and
subsequently key to the catalytic functions – of a group of enzymes named metalloenzymes.2 The
association of the metal ion with the active site varies in metalloenzymes: in some
metalloenzymes the metal ion is permanently attached to the active site while in others the metal
ion is a labile part of a coenzyme.1 Metalloenzymes are involved in a variety of physiological
processes, ranging from the biosynthesis of DNA and certain amino acids to respiration and
digestion.3
Zinc, a trace metal in the human body and one of the most biologically important transition
metals, plays a central role as a structural component of proteins and as a cofactor for enzyme
catalysis. Behind iron, zinc is the second most abundant metal in the human body, with an adult
human body containing 2-3 g of zinc.4 In biological systems, zinc displays only one oxidation
state, that of a divalent cation [zinc(II)].1, 4a
The role of zinc in biology has been studied for over a century. In 1869, Raulin demonstrated
the necessity of zinc for the growth of mold Aspergillus niger and the continual study of zinc has
further unveiled the importance of zinc in growth and development.5 Over 300 zinc
metalloenzymes have been identified since the discovery of the first zinc metalloenzyme,
carbonic anhydrase II, in 1940 by Keilan and Mann.4b Zinc is integral to the catalytic activity of
many metalloenzymes, and it has been clearly demonstrated that removal of zinc results in loss
of enzymatic activity of those enzymes.4b
A few key characteristics of zinc can explain its prevalence in nature. The zinc ion is a small
ion with a radius of 0.65 Å and thus has a high charge density.6 Unlike the other members of the
first row transition metals, zinc has a filled d orbital, which explains its small radius. Zinc
therefore has high electron affinity and is a strong Lewis acid.4b, 6 Zinc does not participate in
redox reactions, making zinc(II) a more physiologically stable ion and an ideal, redox-stable,
Lewis acid type catalyst.4b Other first row metals such as copper and nickel have similar Lewis
acidic properties to zinc, but zinc exhibits only one oxidation state, making zinc more favorable
in biological systems as it avoids the generation of harmful free radicals.7 Although cadmium is
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chemically similar to zinc, it is not nearly as prevalent in the body. In fact, cadmium is
carcinogenic, thus zinc has been evolutionarily selected over cadmium.8 The basis of the
selection of zinc lies in its chemical stability, nontoxicity and stereochemical flexibility.
Another advantage offered by zinc is its flexible coordination geometry. Zinc’s filled d
orbital results in Zn2+ having a ligand-field stabilization energy of zero in all coordination
geometries.4b Zn2+ has been most commonly observed in a tetrahedral or distorted tetrahedral
geometry with a coordination number of four, but some enzymes contain zinc ions that have
been determined to have trigonal bipyramidal or octahedral geometries.4b, 8,9 Catalytic zinc ions
are usually bound in active sites of enzymes by three or four residues and have another
coordination site occupied by an activated water molecule. The water bound to the zinc can play
a variety of critical roles in the catalysis including activation via ionization, polarization by a
base to generate a nucleophile, or being displaced by the substrate.10 For example, in hydrolytic
zinc metalloenzymes, the Zn2+ activates the hydroxide by either orienting the hydroxide such that
it is at the appropriate position for nucleophilic attack of substrate or by adjusting the
electrostatics of metal-solvent coordinate interactions, making the metal-bound hydroxide the
predominant species at physiological pH.9 The active site Zn2+ has been observed to be bound by
histidine, glutamate, aspartate or cysteine residues, with histidine being the most frequent
coordinating amino acid of the catalytic site residues.10
Metalloenzymes are involved in a variety of biological processes and their over-expression
often coincides with different diseases. Metalloenzymes such as histone deacetylase (HDAC)
play an important role in tumor cell proliferation, angiogenesis and many other processes
relevant to cancer.11 The American Cancer Society estimates that over 500,000 deaths from the
four major cancers – colon and rectum, lung and bronchus, breast, and prostate – will occur in
the United States in 2015. Developing new therapies to treat cancer is a major focus of the
pharmaceutical industry as well as in academia. Inhibition of metalloenzymes is often dependent
on the ability of the inhibitor to bind the active site metal.12 Understanding the energetics of this
active site metal-inhibitor interaction can thus aid in the design of more potent inhibitors. Current
FDA-approved metalloenzyme inhibitors are associated with many adverse effects as we have
yet to identify a way to target inhibitors to specific metalloenzymes.13 Without high specificity,
the inhibitors also bind other metalloenzymes and metals present in the body, giving rise to
negative side effects such as nausea and blood disorders, among others.
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The interaction of metalloenzymes with inhibitors is most often studied using isolated
enzyme. Such studies give information about the overall energetics of the interaction but do not
allow for the extraction of the energetic contribution of individual components of the interaction
– such as active site metal binding by inhibitor. Although the energetics of the inhibitor binding
to the free metal ion can be determined, it does not equate the energetics of the inhibitor binding
to the active site metal ion. A better alternative is to use an enzyme structural mimetic formed by
a metal ion bound to a ligand consisting of the same or similar set of coordinating atoms as in the
enzyme active site.
In this work, the interactions of five different small molecule ligands with Zn2+ were studied
using Isothermal Titration Calorimetry (ITC) to identify suitable ligands for the formation of
binary complexes as potential HDAC structural mimetics (Section 2.2). Three potential HDAC
structural mimetics were further studied with the metal chelator 8-hydroxyquinoline (Section
2.3.1), which was selected from among the zinc-chelating HDAC inhibitors for its strong metal
ion affinity necessary for unambiguous conclusion of the feasibility of the binary complex as an
HDAC structural mimetic. The thermodynamics of the binary complexes interacting with the
HDAC inhibitor, acetohydroxamic acid (AHA), were also evaluated using ITC (Section 2.3.2).
Additionally, the interactions of Zn2+ and Ca2+ with three members of the tetracycline family
(which have been shown to inhibit matrix metalloproteinases through interaction with structural
Ca2+ and Zn2+) were studied using ITC and UV-Vis spectroscopy (Sections 3.2-3.4). The results
of the studies can potentially be used to design more potent metalloenzyme – specifically HDAC
and MMP – inhibitors with greater enzyme specificity.
1.2 Isothermal Titration Calorimetry (ITC)
ITC is a titration instrument commonly used to determine the thermodynamic parameters
of different molecular interactions in solution by measuring the heat generated or adsorbed by
interactions upon a series of injections of one reactant (titrant) into another (titrate). The titrant
solution is placed in the syringe, and injected in a series of small volumes (8-15 μL) into the 1.4
mL of titrate solution contained in the reaction cell. Since the titrant is injected in such small
volumes, a large dilution factor is associated with the injection. The raw data from the
experiment is plotted as the heat power (μWatts) versus time (minutes). Raw data consisting of
downward, negative peaks indicate an overall exothermic process, while upward, positive peaks
indicate an overall endothermic process. The area under each peak is integrated and normalized
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to kJ/mole of titrant and plotted against the titrant:titrate molar ratio. This plot is fit with a nonlinear least squares curve using a suitable model such as the one-set-of-sites (all titrant binding
sites on the titrated molecule are thermodynamically identical) or two-sets-of-sites models (with
two different kinds of titrant binding sites on each titrate molecule) included in the Origin 7.2
software (OriginLab, Northhampton, MA). The fit yields the values of enthalpy change for the
binding reaction (ΔH°), the equilibrium association constant (Ka), and the stoichiometric ratio
between the two interacting species in the resulting complex (n). These values can then be used
to calculate other useful parameters such as the standard Gibbs free energy change (ΔG°),
equilibrium dissociation constant (Kd) and the entropy change for the reaction (ΔS°). Further
information about ITC analysis is provided in the Experimental Methods in Chapter 4.1.
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Chapter 2. Development and Inhibition Studies of Histone Deacetylase Structural Mimetics
2.1 Introduction to Histone Deacetylases and Their Inhibition
Cancer treatments often target various enzymes involved in the uncontrolled replication
of cancer cells. One such target is the enzyme histone deacetylase (HDAC). HDACs are
hydrolytic metalloenzymes that remove the acetyl groups on N-acetyl lysine residues in histone
proteins (Figure 2.1).11 HDACs have also been shown to modify the acetylation of non-histone
proteins, such as transcription factors and cytoplasmic proteins.13 HDACs, together with histone
acetyl transferases (HATs) – which transfer an acetyl group from acetyl CoA to lysine residues –
balance acetylation levels in histones and other proteins.14 Deacetylation plays an important role
in epigenetic regulation.15 Histone acetylation levels are critical in the regulation of gene
transcription. Histone proteins are essential components of the higher-order DNA structure
chromatin. Chromatin, which consists of the basic units called nucleosomes formed by wrapping
147 bp of DNA around a histone octamer core formed by four histone partners, an H3-H4
tetramer and two H2A-H2B dimers (Figure 2.2).16 Chromatin controls transcription and plays a
major role in gene regulation.

Figure 2.1. Reaction catalyzed by HDACs. Representative scheme of histone lysine deacetylation by
HDACs is shown. HDACs catalyze the removal of the acetyl group from lysine in the presence of water,
releasing an acetate molecule.

The histone core is important for establishing different ionic interactions between
nucleosomes in chromatin. Chromatin can adopt different structural conformations depending on
modifications that occur in the protruding histone tails, specifically H-3 and H-4 which are
targeted for various post-translational modifications such as acetylation, N-methylation, or
phosphorylation.13, 16 Acetylation of lysine in histone neutralizes the positive charge of histone
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lysine residues and results in a more relaxed chromatin state and subsequently gene-transcription
activation through greater accessibility of the transcription machinery.13-14 Deacetylation of
histone lysine residues increases ionic interactions between positively charged histones and
negatively charged DNA, resulting in a more compact, condensed chromatin state and
transcriptional gene silencing via limited accessibility of the transcription machinery.14 Inhibition
of HDACs prevents deacetylation, which results in improper DNA transcription and prevents
cell reproduction, ultimately resulting in cell death. Thus, inhibition of HDAC can be used as a
therapeutic approach to kill cancer cells.

Figure 2.2. The nucleosome. The nucleosome is the basic unit of chromatin and consists of DNA
wrapped around a histone octamer.

To date, eighteen mammalian HDAC enzymes have been identified. HDACs have been
grouped into four classes based on their sequence homology with yeast protein orthologues and
enzymatic activity.17 This work focuses on inhibition of the so-called “classical” HDACs which
include class I, II, and IV HDACs, all of which are Zn2+-dependent enzymes that can be inhibited
by Zn2+ chelating compounds such as trichostatin A.13, 17 Class III HDACs (SIRT1, 2, 3, 4, 5, 6,
and 7), also called sirtuins, are Zn2+-independent and have a different catalytic mechanism
requiring NAD+ as a cofactor.17 Class I HDACs (HDAC1, 2, 3, and 8) are ubiquitously expressed
in all tissues, homologous with yeast Rpd3, and are predominantly located in the nucleus.13-14
Class II HDACs are homologous to yeast Hda1 and shuttle between the nucleus and cytoplasm
in response to cellular signals. Class II HDACs are further subdivided based on structure into
class IIa (HDAC4, 5, 7, and 9) and class IIb (HDAC6 and 10). HDAC11 is the only member of
the class IV HDACs and is homologous with Class I and II HDACs.13
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Almost all of the classical HDACs function as a multi-protein complex and have a
common, highly conserved active site. The HDAC active site is accessible from the surface of
the enzyme through a hydrophobic tunnel formed by Phe152, Gly151, His180, Phe208, Met274
and Tyr306 (Figure 2.3). At the base of the hydrophobic tunnel is the catalytic Zn2+, which is
coordinated by two Asp residues and one His residue, as well as an activated water molecule
(Figure 2.4).

Figure 2.3. HDAC hydrophobic tunnel. The SAHA linker transcends the hydrophobic pocket and the
hydroxamic acid group binds the active site Zn2+. Left image shows the residues that make up the
hydrophobic tunnel in teal in stick form with SAHA shown in stick form in red. Right image shows the
residues that make up the hydrophobic tunnel as teal spheres, with SAHA in red in the pocket and binding
the active site Zn2+ (yellow sphere). Image generated in pymol using PDB 1T69

Figure 2.4. HDAC active site. The HDAC active site zinc is bound to active site residues Asp178,
His180, and Asp267 and also coordinates to an activated water molecule (left). The active site Zn2+
(shown in yellow) is bound in the active site by Asp178 (green), His180 (blue), and Asp267 (purple)
(right). Image generated in pymol using PDB 1T69

Histone deacetylase inhibitors (HDIs) have garnered interest as promising cancer
therapeutic agents because HDAC function and/or expression are perturbed in a variety of
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cancers. Inhibition of HDAC can result in a variety of antitumor effects such as inhibiting
proliferation, inducing apoptosis, disruption of angiogenesis and cell cycle arrest.11 Several HDIs
have been isolated as natural products or synthesized. Clinically relevant HDIs are in different
chemical classes such as hydroxamic acids, carboxylic acids, benzamides or cyclic peptides.18
Trichostatin A (TSA) was isolated from Streptomyces hygroscopicus in 1976 by Tsuji et al. and
was the first natural hydroxamic acid discovered to inhibit HDACs.16, 19 Historically, most HDIs
have been based on the hydroxamic acid functional group. Hydroxamic acids are the most
effective zinc-binding group currently available in both natural and non-natural HDIs.20
However, due to poor pharmacokinetics and severe toxicity as a result of nonspecific metal
binding, other zinc-binding groups are also being explored to improve selectivity and
specificity.11, 20 In general, HDIs are composed of three regions: a surface recognition domain, a
linker, and a Zn2+-binding group (Figure 2.5). The surface recognition domain, which is
primarily responsible for enzyme selectivity, blocks the entrance of the active site pocket and the
linker connects the surface recognition domain and Zn2+-binding group.11

Figure 2.5. The structure of SAHA and the general features of HDAC Inhibitors. HDAC Inhibitors are
generally composed of three regions: a surface recognition domain, a Zn2+-binding group, and a linker.

There are currently three HDIs that have been approved by the Food and Drug Administration
(FDA) for cancer therapy: vorinostat (Zolinza®, Merck) and romidepsin (Istodax®, Celgene)
which are used to treat cutaneous T-cell lymphoma, as well as panobinostat (Farydak®,
Novartis) which was recently approved to treat multiple myeloma.18, 21 Vorinostat and
panobinostat are both hydroxamic acid HDIs while Romidepsin is a cyclic peptide HDI.
Vorinostat is suberoylanilide hydroxamic acid (SAHA), and was the first HDI approved
by the FDA for clinical use. SAHA inhibits HDAC with its linker blocking the hydrophobic
tunnel and the hydroxamic acid group functioning as the Zn2+-binding group (Figure 2.5). When
the SAHA binds Zn2+, it displaces the activated water on Zn2+ forming a complex with the Zn2+
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coordinating in a trigonal bipyramidal geometry. SAHA targets Class I and II HDACs only and
compared to other HDIs has medium potency in inhibiting HDAC as based on its binding
constant and rapid reversibility in binding HDAC.19 Other HDIs have been discovered that are
far more potent than SAHA, but are also typically more toxic as revealed in in vivo studies.19 The
most commonly used HDIs, such as SAHA, target multiple HDACs, making it challenging to
identify the extent of inhibition necessary to achieve therapeutic effect. When multiple HDACs
are being inhibited, it is difficult to determine whether the therapeutic effect observed is a result
of inhibition of a specific HDAC isoform or combined effects of inhibition of multiple HDACs.11

Figure 2.6. SAHA in HDAC8 active site. Top image is SAHA (red) in the active site of HDAC8, with its
hydroxamic acid group binding the catalytic Zn2+ (yellow) held in place by Asp178 (green), His180
(blue), and Asp267 (purple). Bottom image shows the interactions of SAHA with the HDAC active site.
In addition to coordinating to the active site Zn2+ (yellow), SAHA is also coordinated by His142 (orange),
His143 (blue), and Tyr306 (green). Image generated in Pymol using PDB 1T69.

Almost all HDACs exist as multiprotein complexes consisting of different HDAC
isoforms. Thus, how inhibition of one HDAC affects the activity of another HDAC is an
additional factor to consider. Bantscheff et al. reported different inhibitory activity and enzyme
specificity of HDIs depending on whether the studies were done using multi-HDAC complexes
or isolated HDACs.22 One of the critical features of HDIs from which they derive their strong
affinity and high potency is their Zn2+-binding group, which has affinity for other metal ions as
well. The hydroxamic acid group in the inhibitor serves to bind the active site Zn2+ but has
overall low enzyme specificity. This lack of specificity results in the hydroxamic acid group
binding and inhibiting other metalloenzymes, with toxicity as a consequence. Because metal ions
play important roles in many enzymatic reactions, targeting metalloenzymes with specificity is
critical to avoid undesirable side effects.
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The disadvantage for the current FDA approved HDIs is that they have poor enzyme
specificity and subsequent adverse side effects; thus, use of all current HDIs in cancer treatment
is associated with adverse effects such as nausea, vomiting, fatigue, and blood disorders such as
anemia and leukopenia.13 A dissection of the individual contribution of each part of the enzymeinhibitor interaction can aid in the intelligent design of more specific HDAC inhibitors. The
crystal structure of SAHA bound to the active site of an HDAC enzyme has been obtained,
revealing a SAHA coordinating to the active site Zn2+ via its hydroxamic acid moiety in addition
to interacting with the nonpolar wall of the tunnel via the linker and cap regions. However, a
static structure lacks information about the thermodynamics of the interaction.23 The overall
interactions of different hydroxamic acid ligands with HDAC8 have been studied using
Isothermal Titration Calorimetry (ITC).24 The results provide the thermodynamics of the overall
interaction of the inhibitor with the active site but yield little insight into the specific contribution
of the different parts of the inhibitor
Breaking down the system such that only one interaction of the whole process is studied
provides information about how one specific component of the interaction contributes to the
overall interaction. In an effort to understand the contribution of Zn2+ to overall inhibitor binding,
ITC had been used in the Jin lab to study the interaction of SAHA with Zn2+. The results from
these studies yielded a rather weak affinity constant (Ka ~ 400 M-1) with uncertain stoichiometry.
In fact, multiple different n values – of no higher than 0.5 mol SAHA per Zn2+ – fit the data well
as judged by the reduced chi squared value. The uncertainty in the n value stemmed from the
very weak affinity constant, rendering the calculated c value (c = n*Ka*[cell]) to fall outside the
optimal window of 1-1000 for accurate extraction of the binding parameters.
Regardless of the accuracy of the inhibitor and Zn2+ study, the binding of inhibitor to free
Zn2+ in solution does not equate the binding of inhibitor to active-site Zn2+ due to differences in
entropy of the free versus active-site Zn2+. With these thoughts in mind came the idea to develop
a HDAC structural mimetic by synthesizing a ligand that will strongly chelate Zn2+ in the same
way that the active site residues bind Zn2+ and use this mimetic system in ITC studies with
different inhibitors.
Of particular interest for this project was to develop a HDAC structural mimetic and use
it to study its interaction with different inhibitors using ITC, then compare the results with those
reported by Singh et al. for hydroxamic acid ligands interacting with HDAC8.24 ITC experiments
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provide valuable physical parameters for interactions such as the stoichiometry (molar ratio of
the titrant to titrate in the resulting complex), enthalpy change, entropy change, and equilibrium
association constant. HDAC8 has been the most heavily studied HDAC enzyme as it functions as
a single polypeptide, rather than as a high-molecular-weight multiprotein complex as all other
structural HDACs are found.25 In HDAC8, the zinc ion is coordinated by three residues, His180
using the imidazole nitrogen, Asp178 and Asp 267 using their carboxyl groups; thus, the goal
was to develop a ligand to mimic these residues in order to create the HDAC structural mimetic.
2.2 ITC studies of interactions of small molecule ligands with Zn2+
The first goal of this project was to identify an HDAC structural mimetic. A series of
ligands were studied in an effort to find the best candidate for serving as an HDAC structural
mimetic. To be considered as a promising HDAC structural mimetic, the ligand had to meet a
variety of requirements. It was imperative that the ligand strongly chelate Zn2+ and the resulting
complex remain intact while it binds to inhibitor. If the inhibitor were to have a stronger affinity
for zinc than the ligand does, the inhibitor would displace the ligand. Previous work in the Jin lab
demonstrated that two hydroxamic acid inhibitors, SAHA and AHA, had Zn2+ affinity constants
around 400 M-1. Based on the affinity of the HDIs for Zn2+, the desired binding constant for the
ligand and zinc interaction was greater than 105 M-1 to ensure the ligand would not be displaced
during inhibitor binding. A second requirement was that the stoichiometric ratio of the ligand to
Zn2+ in the complex be 1:1. This ensures that there is ample space left on zinc for inhibitor
binding. Zn2+ typically assumes a tetrahedral or trigonal bipyramidal geometry in solution,8 thus
the ligand should bind Zn2+ but still leave enough space and coordination sites on Zn2+ open for
the inhibitor to bind. If two ligands are bound to each Zn2+ ion, no coordination site will be
available for inhibitor binding. The final requirement was that the structural mimetic complex
must be soluble at concentrations necessary for ITC study (1-5 mM) in 50 mM NEM buffer
(0.150 M NaCl, pH 6.80) and/or a 60:40 (by volume) mixture of MeOH: buffer (50 mM NEM,
0.150 M NaCl) at pH 6.80. These two solvent systems were the conditions that were used in
similar studies. From here on out unless otherwise stated the 50 mM NEM buffer (0.150 M
NaCl, pH 6.80) will simply be referred to as “NEM buffer” and the 60:40 (by volume) mixture
of MeOH: buffer (50 mM NEM, 0.150 M NaCl) at pH 6.80 will be referred to as “MeOH:buffer
mixture.”
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2.2.1 N-(2-(1-methylimidazolyl)methyl)iminodiacetic acid (DA2Im) with Zn2+
In an effort to mimic the structure of the actual amino acid residues that coordinate the
zinc in the active site of HDAC, N-(2-(1-methylimidazolyl)methyl)iminodiacetic acid (DA2Im)
(Figure 2.7), was synthesized. The interaction of DA2Im with Zn2+ had been studied by Canary
and coworkers using potentiometric titrations.26 The authors investigated the effect of pH on the
stoichiometric ratio of Zn2+ to ligand in the zinc-ligand complex and found that DA2Im
complexed with Zn2+ in a 1:1 ratio.26 Based on these results, DA2Im appeared to be a promising
ligand to create the HDAC structural mimetic. The imidazole was incorporated to reflect the
His180 and the carboxylic acids to mimic Asp178 and Asp267, the three residues that coordinate
Zn2+ in the HDAC8 active site. Because aqueous solubility is an issue for some HDAC
inhibitors, the interaction between DA2Im and zinc was studied in two solvent systems: NEM
Buffer and the MeOH:buffer mixture.

Figure 2.7. N-(2-(1-methylimidazolyl)methyl)iminodiacetic acid (DA2Im). DA2Im is a potentially
tetradentate ligand that can bind Zn2+ with its carboxylic acid oxygens, tertiary amine, and imidazole
nitrogen.

Injection of ZnCl2 (0.15 mM) into DA2Im (0.03 mM) in NEM buffer demonstrated that
DA2Im had a high affinity for Zn2+ (Ka of (1.2 ± 0.5) × 108 M-1), but afforded a perplexing
stoichiometric ratio of 0.66 ± 0.07 (Figure 2.8 and Table 2.1). The stoichiometric ratio of 0.66 ±
0.07 (Zn2+:DA2Im) corresponds to a stoichiometry of 2 DA2Im: 3 Zn2+. This stoichiometry
renders the DA2Im ligand an unsuitable ligand to create the HDAC structural mimetic.
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Figure 2.8. Raw data (top panel) and binding isotherm (bottom panel) for titration of 0.15 mM ZnCl2 into
0.03 mM DA2Im in NEM buffer at 25 °C.
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When the injection order was reversed such that DA2Im (0.15 mM) was titrated into ZnCl2 (0.03
mM) in NEM buffer, the results were indicative of two binding events occurring (Figure 2.9). It
is well established that carboxylic acids in fluid states, both liquid and gas, primarily exist in the
dimer form (Figure 2.9).27 Hydrogen bonds between the carboxylic acids result in the formation
of these dimers. The two binding events observed may correspond to the dissociation of the
dimeric ligand as it is diluted over 100-fold upon injection into the reaction cell, followed by
binding of the monomeric ligand to Zn2+.

Figure 2.9. Hydrogen Bonded Dimer of a carboxylic acid. Ligands containing carboxylic acid groups
tend to dimerize when used as the titrant in ITC due to relatively high concentration. Thus all ITC
experiments for ligands containing carboxylic acid were done with Zn2+ as the titrant and the ligand as
titrate.

A control run of DA2Im into NEM buffer was performed and it was observed that the
trend in the resulting binding isotherm had the same trend as for the titration of DA2Im into
ZnCl2 (Figure 2.10). The heat for titrant into buffer titration is not an exact match for the actual
titrant dilution heat when titrant is injected into ZnCl2 solution. When the control heat is as
significant as in the present case, the inability to obtain the exact titrant dilution heat prevents the
extraction of binding parameters. Binding thermodynamics and stoichiometry for DA2Im with
Zn2+ in buffer was therefore obtained from the injection of Zn2+ into DA2Im only, as shown in
Figure 2.8 (vide supra).
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Figure 2.10. Overlay of binding isotherms for DA2Im titrated into ZnCl2 in NEM buffer experiment
(squares) and the control experiment of DA2Im titration into NEM buffer (triangles) at 25 °C.

The interaction of DA2Im with Zn2+ was also studied in MeOH:buffer mixture. The
resulting binding isotherms were complex for both injection orders. When ZnCl2 (0.15 mM) was
titrated into DA2Im (0.03 mM), the binding isotherm exhibited multiphasic nature (Figure 2.11).
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Due to the inability to determine the actual titrant dilution heat that can be accurately subtracted
to remove heat not stoichiometrically correlated with the DA2Im-Zn2+ binding event, it is
impossible to de-convolute the binding isotherm to extract the correct stoichiometry and
thermodynamic binding parameters.
The injection order was reversed such that DA2Im (0.15 mM) was titrated into ZnCl2
(0.03 mM) in the MeOH:buffer mixture. The resulting binding isotherm could not be fit with the
binding models provided in the Origin 7.2 software (OriginLab, Northhampton, MA) (Figure
2.12). The control heat for a solution of 0.15 mM DA2Im being titrated into the MeOH:buffer
mixture demonstrated that the dilution heat of DA2Im was large and exothermic. The control
heat being larger than that of the reaction heat suggests that the interaction between Zn2+ and
DA2Im is possibly endothermic in the MeOH:buffer mixture. No thermodynamic values were
extracted from these experiments as the data are obscured by the overwhelming control heat. The
complex nature of the titrant (DA2Im) dilution heat is likely caused by the complex solvation
heat and/or dimer dissociation heat due to the abundance of basic nitrogens and carboxylic acids
in the ligand. Again, dimerization of the ligand in the syringe is also a likely cause for the large
dilution heat. In conclusion, no stoichiometry and binding thermodynamics could be extracted
for DA2Im with Zn2+ in the MeOH:buffer mixture.
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Figure 2.11. Raw data (top panel) and binding isotherm (bottom panel) for titration of 0.15 mM ZnCl2
into 0.03 mM DA2Im in the MeOH: Buffer mixture at 25 °C. The abundance of basic nitrogens and
carboxylic acids in the DA2Im likely results in complex solvation heat and/or dimer dissociation heat.
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Figure 2.12. Overlay of binding isotherms for 0.15 mM DA2Im titration into 0.03 mM ZnCl2 in the
MeOH:buffer mixture (squares) and the control run of 0.15 mM DA2Im into MeOH:buffer mixture at
25 °C (triangles). In the MeOH:buffer mixture, the control heat for titration of DA2Im into the solvent
system is greater than the heat of the interaction when DA2Im is titrated into ZnCl2.
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Table 2.1. Thermodynamic parameters from ITC study of DA2Im interaction with Zn2+ in NEM buffer
pH 6.80*
n
Ka
Kd
ΔS°
ΔG°
ΔH°
TΔS°
(kcal/mol)
(kcal/mol)
(kcal/mol)
(Zn2+/DA2Im)
(M-1)
(μM)
(cal/mol⋅K)
(1.2 ± 0.5 ) ×
0.66 ± 0.07
(9 ± 3) x10-3 -11.0 ± 0.2 -1.7 ± 0.6
31 ± 2
9.3 ± 0.7
108
*Titration of 0.15 mM ZnCl2 into 0.03 mM DA2Im

The interaction of DA2Im with ZnCl2 was only successfully determined in NEM buffer when
ZnCl2 was titrated into DA2Im. The stoichiometric ratio of 0.66 ± 0.07 (Zn2+:DA2Im) and the
equilibrium affinity constant of (1.2 ± 0.5 ) × 108 M-1 differ significantly from those obtained by
Canary and coworkers.26 The ITC experiments were performed in a buffer with conditions
including ionic strength, anion identity (chloride) and controlled pH that more closely
approximate a biological system. The potentiometric experiments were performed in water with
perchlorate as the counterion at varying pH that resulted from titration of NaOH. Chloride ions
will compete with the DA2Im ligand to bind Zn2+ whereas perchlorate ions will not. The
differences in the n values obtained from the two types of experiments are not surprising given
the difference in conditions. Also, the stability constant from potentiometric titration does not
include accompanying equilibria such as ligand deprotonation that likely occurs upon ligand
coordination to Zn2+. In the same potentiometric study by Canary and coworkers,26 the
interactions of Zn2+ with several other ligands were reported. Four of the ligands were selected in
this work and studied using ITC as detailed below.
2.2.2 Nitrilotriacetic acid (NTA) with Zn2+
Nitrilotriacetic acid (NTA) is one of the ligands that Canary and coworkers26 used in the
potentiometric titration study with Zn2+. The interaction of commercially available NTA with
Zn2+ was investigated in 50 mM NEM buffer (0.15 M NaCl, pH 6.80) using ITC. NTA is a
tetradentate ligand that can potentially bind Zn2+ with its tertiary amine and three carboxylic acid
oxygens (Figure 2.13).
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Figure 2.13. Nitrilotriacetic Acid (NTA). NTA is a tetradentate ligand that can potentially bind Zn2+ with
its three carboxylic acid oxygens and its tertiary amine.

Experiments in the MeOH:buffer mixture were not possible as NTA was insoluble in the solvent
system at the concentrations necessary for ITC. Titration of a solution of ZnCl2 (0.3 mM) into a
solution NTA (0.06 mM) in NEM buffer (Figure 2.14) revealed a high affinity of NTA for Zn2+
(2.1 ± 0.4) × 107 M-1), and a stoichiometric ratio of 0.68 ± 0.1 NTA per Zn2+ corresponding to 2
NTA: 3 Zn2+, rather than the 1:1 complex preferred for a HDAC structural mimetic for inhibitor
binding study (Table 2.2). Unfortunately, the HDAC inhibitors to be studied with the mimetic
complex, except for AHA, were soluble only in the MeOH:buffer mixture, thus NTA was not
suitable for the inhibitor studies due to insolubility in the solvent mixture and no further
experiments were performed.
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Figure 2.14. Raw data (top panel) and binding isotherm (bottom panel) for titration of 0.3 mM ZnCl2 into
0.06 mM NTA in NEM buffer at 25 °C.
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Table 2.2. Thermodynamic parameters from ITC study of NTA interaction with Zn2+ in NEM buffer*
n
Ka
Kd
ΔG°
ΔH°
ΔS°
TΔS°
(Zn2+/NTA)
(M-1)
(μM)
(kcal/mol) (kcal/mol) (cal/mol⋅ K) (kcal/mol)
0.68 ± 0.1
21 ± 1
6.2 ± 0.4
(2.1 ± 0.4) ×107 0.049 ± 0.009 -10.0 ± 0.1 -3.7 ± 0.3
*Titration of 0.3 mM ZnCl2 into 0.06 mM NTA

2.2.3 Tris(2-pyridylmethyl)amine (TPA) with Zn2+
Commercially available tris(2-pyridylmethyl)amine (TPA) (Figure 2.15) was explored as
a potential ligand to form the HDAC structural mimetic. TPA is another ligand that Canary and
coworkers studied with Zn2+ using potentiometric titrations.26 TPA is a tetradentate ligand that
can potentially bind Zn2+ with the three pyridine nitrogens and a tertiary amine nitrogen.

Figure 2.15. Tris(2-pyridylmethyl)amine (TPA). TPA is a tetradentate ligand that can potentially bind
Zn2+ with its three pyridine nitrogens and its tertiary amine.

TPA was found to be insoluble in NEM buffer at the concentration necessary for ITC
experiments; therefore, ITC experiments were carried out in MeOH:buffer mixture only. When
TPA (3 mM) was titrated into ZnCl2 (0.3 mM), the resulting data was fit to a one-set-of-sites
binding model (Figure 2.16) which yielded a high affinity of TPA for Zn2+
(Ka = (7 ± 4) × 106 M-1) and a stoichiometric ratio of 0.66 ± 0.02 TPA per Zn2+, corresponding to
a 2 TPA: 3 Zn2+ complex (Table 2.3). This stoichiometric ratio does not meet the requirement for
a 1:1 binary complex for it to be a HDAC structural mimetic. This result again shows how
different conditions can affect metal binding as Canary and coworkers reported a 1:1 ratio in
potentiometric titrations.26
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Figure 2.16. Raw data (top panel) and binding isotherm (bottom panel) for titration of 3 mM TPA into
0.3 mM ZnCl2 in MeOH:buffer mixture at 25 °C.
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When ZnCl2 (0.3 mM) was titrated into TPA (0.03 mM), curve fitting to one set of sites
model resulted in a stoichiometry of 0.85 ± 0.06 Zn2+ per TPA (Figure 2.17) which approximates
a 1:1 Zn2+:TPA complex (Table 2.3). The observed stoichiometry, or complex composition, is
therefore dependent on the injection order. The difference likely resulted from different
availability of the titrant and the titrate in the two injection orders. The ITC syringe holds 280 μL
of titrant and the reaction cell holds 1400 μL of titrate. Despite the lower total volume, the titrant
is in excess at the end of the experiment as titrant was at a much greater concentration than the
titrate. When the titrant concentration was ten times that of the titrate, at the end of the
experiment there was twice as many moles of the titrant in the reaction cell than moles of titrate.
When ZnCl2 was the titrant, this injection order evidently settled on the 1:1 binding because of
excess Zn2+ at the end of the titration. When the ligand was the titrant and thus ligand was in
excess at the end of the titration, this titration order evidently settled on the formation of
complexes having multiple ligands bonding to the same Zn2+ ion. This is because when Zn2+ is
limited, multiple ligands will attempt to bind the limited amount of Zn2+ available. When
different stoichiometries are observed for different injection orders, the equilibrium association
constants also differ. The Ka obtained when TPA was the titrant was an order of magnitude
greater than when ZnCl2 was the titrant (Table 2.3).
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Figure 2.17. Raw data (top panel) and binding isotherm (bottom panel) for titrations of 0.3 mM ZnCl2
into 0.03 mM TPA in MeOH:buffer mixture at 25 °C.
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Table 2.3. Thermodynamic parameters from ITC study of TPA interaction with Zn2+*
ΔS°
Injection
n
ΔG°
ΔH°
TΔS°
Ka (M-1)
Kd (μM)
Order
(TPA/Zn2+)
(kcal/mol)
(kcal/mol)
(cal/mol⋅K) (kcal/mol)
TPA into
0.66 ± 0.02
(7 ± 4) × 106
0.2 ± 0.1
-9.3 ± 0.4
-15.7 ± 0.4
-21 ± 3
-6.4 ± 0.8
Zn2+
2+
Zn into
0.85 ± 0.06
(3 ± 1) ×105
4±2
-7.4 ± 0.3
-16.1 ± 0.8
-29 ± 0.3
-9 ± 1
TPA
*Titration of 3 mM TPA into 0.3 mM ZnCl2 and also titration of 0.3 mM ZnCl2 into 0.03 mM TPA in MeOH:buffer.

2.2.4 Bis(2-picolyl)amine (BPA) with Zn2+
Zn2+ coordination complexes primarily exist in solution with a tetrahedral or trigonal
bipyramidal geometry.4b One concern with using tetradentate ligands to form the zinc:ligand
binary complex as an HDAC active site structural mimetic is that if the Zn2+ coordinates to four
atoms of the same ligand, there will be insufficient coordination sites left on Zn2+ for the
inhibitor binding due to the tetrahedral and trigonal bipyramidal geometries preferred by Zn2+
providing only four or five coordination sites, respectively. With this concern in mind,
commercially available bis(2-picolyl)amine (BPA) was studied as a potential ligand to develop a
HDAC active site structural mimetic. BPA was selected due to its structural similarities with
TPA. BPA is a tridentate ligand that can potentially bind Zn2+ with two pyridine nitrogens and
the nitrogen of the secondary amine (Figure 2.18).

Figure 2.18. Bis(2-picolyl)amine (BPA). BPA is a tridentate ligand that can potentially bind Zn2+ with the
two pyridine nitrogens and secondary amine.

BPA was soluble in both the buffer and the MeOH:buffer mixture. ITC experiments were
performed by titrating BPA (3 mM) into ZnCl2 (0.3 mM) in either NEM buffer (Figure 2.19) or
the MeOH:buffer mixture (Figure 2.20). Results from experiments in both solvent systems were
fit to a two-sets-of-sites binding model. The formation of a 1 BPA:1 Zn2+ complex has a high
affinity (Ka ~ 107 M-1) and the binding of a second BPA has a four-orders of magnitude lower
affinity (Ka ~ 103 M-1) (Table 2.4).

	
  

34	
  

	
  

Figure 2.19. Raw data (top panel) and binding isotherm (bottom panel) for titration of 3 mM BPA into
0.3 mM ZnCl2 in NEM buffer at 25 °C.
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Figure 2.20. Raw data (top panel) and binding isotherm (bottom panel) for titration of 3 mM BPA into
0.3 mM ZnCl2 in MeOH:buffer mixture at 25 °C
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In both solvent systems, the first ligand binds with a much stronger affinity as indicated
from the steep transition of the binding isotherm corresponding to the first half (0-80 minutes) of
the total binding isotherm (Figures 2.19 and 2.20). Binding of a second ligand to the 1:1 complex
was evident from the significant heat in the last half of the injections with the heat decreasing
only gradually with each additional injection (Figures 2.19 and 2.20). The second BPA binding
to the initially formed BPA-Zn2+ complex was weak enough that an inhibitor with high affinity
for Zn2+ would be able to displace the second bound BPA. In the HDAC active site, the catalytic
Zn2+ is bound with an activated water molecule in addition to an imidazole nitrogen on His and
two oxyanions from two Asp residues at the active site, thus ideally the HDAC structural
mimetic should be bound in a tridentate ligand and have one or two water molecules bound
depending on whether Zn2+ prefers a tetrahedral or trigonal bipyramidal geometry, respectively.
If BPA is used to form a structural mimetic of HDAC, the inhibitors will be forced to compete
with the second weakly affiliated BPA rather than a water molecule, and competing with the
second BPA versus a water molecule is going to be more energetically costly. Though not ideal
as a mimetic system due to the BPA-Zn2+ complex weakly binding to a second BPA, BPA was
selected as a potential system to create the HDAC structural mimetic to be used for ITC studies
with different inhibitors.
Table 2.4. Thermodynamic parameters from ITC study of BPA interaction with Zn2+*
ΔH°

ΔS°

TΔS°

(kcal/mol)

(cal/mol⋅K)

(kcal/mol)

0.07 ± 0.03
180 ± 30

ΔG°
(kcal/mol)
-9.9 ± 0.5
-5.2 ± 0.2

-10.6 ± 0.1
-5.5 ± 0.9

10 ± 2
-1 ± 4

2.9 ± 0.6
-0.3 ± 1

0.05 ± 0.02

-10.0 ± 0.2

-11.2 ± 0.4

-17 ± 4

-1.2 ± 0.4

-9 ± 3

-12 ± 12

-4 ± 4

Solvent

Fit

n (BPA/Zn2+)

Ka (M-1)

Kd (μM)

Buffer

1
2

1.127 ± 0.006
1.09 ± 0.05

(2.4 ± 0.2) × 107
(7 ± 3) × 103

1

0.83 ± 0.09

(2.3.± 0.6) × 107

MeOH:
Buffer

3

2
0.9 ± 0.1
(7 ± 7) × 10
200 ± 100
-5.1 ± 0.5
*Titration of 3 mM BPA into 0.3 mM ZnCl2 in both solvent systems.

2.2.5 Tris(2-aminoethyl)amine (TREN) with Zn2+
The interaction of commercially available Tris(2-aminoethyl)amine (TREN) with Zn2+
was also studied using potentiometric titrations by Canary and coworkers.26 TREN is a
tetradentate ligand that can potentially bind Zn2+ with three primary amines and one tertiary
amine (Figure 2.21). ITC experiments with TREN consisted of TREN being titrated into a
solution of zinc and were carried out in either NEM buffer or the MeOH:buffer mixture.
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Figure 2.21. Tris(2-aminoethyl)amine (TREN). TREN is a tetradentate ligand that binds Zn2+ with its
three primary amines and tertiary amine.

Titration of TREN (10 mM) into ZnCl2 (1 mM) in the MeOH:buffer mixture demonstrated that
the interaction was exothermic and enthalpically driven with a favorable stoichiometric ratio of
0.94 ± 0.02 (1 TREN: 1 Zn2+) and a Ka of (1.7 ± 0.3) × 106 M-1 (Figure 2.23 and Table 2.5). The
experiments performed in NEM buffer also exhibited a favorable stoichiometric ratio of 0.89 ±
0.06. However, the interaction in buffer was observed to be much weaker (Ka = (4 ± 1) × 104 M-1)
and endothermic (Figure 2.22 and Table 2.5). The weak interaction of the TREN-Zn2+ complex
increases the likelihood of TREN being displaced by the inhibitor when it is used for the
inhibitor binding study. The weak affinity of TREN for Zn2+ in buffer can be potentially
explained by the necessary deprotonation of the amines (pKa ~ 10) prior to binding Zn2+. The
endothermic nature of the deprotonation can also explain the observed overall endothermic heat
for TREN and Zn2+ binding, which is evidently entropically driven (Table 2.5). In the
MeOH:buffer mixture the overall binding was exothermic. This suggests that because of the
presence of the less polar methanol in the MeOH:buffer mixture, the amines in TREN prefer the
uncharged base state thus deprotonation was not necessary prior to Zn2+ binding. The affinity
constants obtained from this ITC study are lower than those obtained in the potentiometric study
by Canary and coworkers.26 Although TREN is tetradentate and exhibited an affinity for Zn2+
weaker than BPA for Zn2+, TREN’s favorable stoichiometry with Zn2+ made it a potential
candidate to create the HDAC active site structural mimetic for the ITC inhibitor studies.
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Figure 2.22. Raw data (top panel) and binding isotherm (bottom panel) for titration of 10 mM Tren into 1
mM ZnCl2 in NEM buffer at 25 °C
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Figure 2.23. Raw data (top panel) and binding isotherm (bottom panel) for titration of 10 mM Tren into
1 mM ZnCl2 in MeOH:buffer mixture at 25 °C
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Table 2.5. Thermodynamic parameters from ITC study of TREN interaction with Zn2+*
Solvent

n
(Tren/Zn2+)

Ka (M-1)

Kd (μM)

ΔG°
(kcal/mol)

ΔH°

ΔS°

TΔS°

(kcal/mol)

(cal/mol⋅K)

(kcal/mol)

Buffer

0.89 ± 0.06

(4 ± 1) × 104

24 ± 9

-6.3 ± 0.2

3.8 ± 0.2

34.0 ± 0.4

10.2 ±
0.1

-4.9 ± 0.1

12.0 ± 0.7

3.6 ± 0.2

MeOH:
0.94 ± 0.02
(1.7 ± 0.3) × 106 0.61 ± 0.09 -8.49 ± 0.09
buffer
*Titration of 10 mM Tren into 1 mM ZnCl2 in both solvent systems.

2.3 ITC studies of the interactions of potential HDAC structural mimetics with inhibitors
The first goal of this project was to identify a ligand that can potentially be used to form
an HDAC structural mimetic. After screening five different ligands, three of the ligands – BPA,
TPA, and TREN – were selected for further ITC studies with HDIs based on their favorable,
strong affinities for Zn2+ and/or their favorable stoichiometric ratios (1:1) of Zn2+ to ligand in the
resulting complex. The ideal HDAC structural mimetic would be formed with a ligand that has a
very high affinity (Ka ≥ 105 M-1) for Zn2+ and binds Zn2+ in a 1:1 stoichiometric ratio while still
leaving adequate coordination sites on Zn2+ for an inhibitor binding. The inhibitors selected for
studying the interaction with the HDAC structural mimetics were 8-hydroxyquinoline (8-HQ),
suberoylanilide hydroxamic acid (SAHA), acetohydroxamic acid (AHA), and 2-benzyl-aminonapthoquinone (NQN-1) (Figure 2.24).

Figure 2.24. 2-benzyl-amino-napthoquinone (NQN-1). NQN-1 has been shown to inhibit HDAC6.

ITC experiments with NQN-1 and SAHA were not performed as NQN-1 was not soluble at
concentrations necessary for ITC in both the NEM buffer and the MeOH:buffer mixture.
2.3.1 8-Hydroxyquinoline interaction with ligand-Zn2+ mixtures as potential HDAC
structural mimetics
8-hydroxyquinoline is a well-known metal ion chelator with a rich diversity of biological
properties.28 Pharmacological applications of the 8-hydroxyquinoline scaffold range from serving
as anticancer agents, anti-HIV agents, antifungal agents, and chelators of metalloenzymes. A
computational study by Chen and coworkers to identify zinc-binding groups for HDAC
inhibition reported that 8-hydroxyquinoline had favorable binding energy with a model active
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site.20 The 8-hydroxyquinoline derivative, NSC3852, has been shown to be an inhibitor of
HDAC2. 8-hydroxyquinoline binds Zn2+ in a bidentate fashion with its phenolic oxygen anion
and nitrogen (Figure 2.25).28

Figure 2.25. 8-Hydroxyquinoline (left) and NSC3852 (right). NSC3852 is a 8-hydroxyquinoline analog
that has been reported to have inhibitory activity against HDAC2.

Due to its poor aqueous solubility, ITC experiments with 8-hydroxyquinoline were only
conducted in the MeOH:buffer mixture. ITC experiments were performed by titrating 8hydroxyquinoline into different HDAC mimetic systems. These HDAC mimetic systems include
BPA-Zn2+, TPA-Zn2+, and TREN-Zn2+ complexes. To determine if the interaction observed when
8-hydroxyquinoline was injected into the ligand-Zn2+ complex was due to 8-hydroxyquinoline
binding to Zn2+ in the ligand-Zn2+ complex or to Zn2+ free in solution, control ITC experiments
were also performed with 8-hydroxyquinoline and free Zn2+ without the ligand present.
The interaction of 8-hydroxyquinoline with ligand-free Zn2+ was studied using ITC for
both titration orders, i.e. the titration of 8-hydroxyquinoline into Zn2+ and the titration of Zn2+
into 8-hydroxyquinoline. Data from injection of Zn2+ into 8-hydroxyquinoline yielded an n value
of 0.39 ± 0.01 Zn2+ per 8-hydroxyquinoline (Figure 2.26). An n value of 0.33 would correspond
to three 8-hydroxyquinoline molecules binding to one Zn2+. An n value of 0.5 would correspond
to two 8-hydroxyquinoline molecules binding each Zn2+. The n value obtained for the 8hydroxyquinoline interaction with Zn2+ was between these two values which was likely a result
of both binding scenarios existing in solution. When three 8-hydroxyquinoline molecules bind
Zn2+ an anionic complex results, whereas a neutral complex is obtained in the 2:1 8hydroxyquinoline:Zn2+ binding mode. Titrations of 8-hydroxyquinoline into Zn2+ were also
performed, which resulted in an n value of 1.98 ± 0.02 8-hydroxyquinoline per Zn2+,
corresponding to a 2:1 (8-hydroxyquinoline:Zn2+) complex (Figure 2.27 and Table 2.6). The
affinity of 8-hydroxyquinoline for Zn2+ was strong, as expected, and there was not a significant
difference between the Ka determined for each injection order, suggesting that the same complex
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was formed from either injection order, which is likely a 1 Zn2+: 2 8-hydroxyquinoline complex.
In fact, zinc and 8-hydroxqyuinoline have been crystalized as bis(8-hydroxyquinoline) zinc(II),
in which two 8-hydroxyquinoline molecules are bound to Zn2+.
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Figure 2.26. Raw data (top panel) and binding isotherm (bottom panel) for titration of 4 mM ZnCl2 into
0.4 mM 8-hydroxyquinoline in MeOH:buffer mixture at 25 °C
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Figure 2.27. Raw data (top panel) and binding isotherm (bottom panel) for titration of 8 mM
8-hydroxyquinoline into 4 mM ZnCl2. in MeOH:buffer mixture at 25 °C

	
  

45	
  

	
  
Table 2.6. Thermodynamic parameters from ITC study of 8-hydroxyquinoline interaction with Zn2+*
ΔS°
Injection
Ka
ΔG°
ΔH°
TΔS°
n
Kd (μM)
Order
(× 105 M-1)
(kcal/mol)
(kcal/mol) (cal/mol⋅ K) (kcal/mol)
8-HQ into
1.98 ± 0.02 1.80 ± 0.03 5.56 ± 0.09 -7.169 ± 0.009
-8.5 ± 0.1
-4.6 ± 0.4
-1.4 ± 0.1
Zn2+
Zn2+ into
0.39 ± 0.01
2.0 ± 0.4
4.9 ± 0.9
-7.2 ± 0.1
-19.8 ± 0.9
-42 ± 4
-13 ± 1
8-HQ
* Titration of 8 mM 8-hydroxyquinoline into 4 mM ZnCl2 and Titration of 4 mM ZnCl2 into 0.4 mM 8hydroxyquinoline. All experiments done in the MeOH:buffer mixture.

ITC experiments were performed to study the interaction between 8-hydroxyquinoline
and various ligand-Zn2+ binary complexes that had been identified as potential HDAC structural
mimetics based on the ligand and Zn2+ ITC studies. The three different binary systems selected
were TPA-Zn2+, BPA- Zn2+, and TREN- Zn2+. Experiments were carried out by titrating 10 mM
8-hydroxyquinoline solution into a solution of ligand-Zn2+ binary complex in the MeOH:buffer
mixture.
Titrations of 8-hydroxyquinoline into BPA-Zn2+ mixture were carried out with varying
ratios of BPA to Zn2+. As shown above, the BPA into Zn2+ titration experiments revealed two
BPA molecules binding each Zn2+, with the first BPA binding Zn2+ with high affinity (Ka ~ 107
M-1) and the second BPA binding four-times more weakly (Ka ~ 103 M-1). Although this was not
an ideal mimetic system because the second BPA binds very weakly, it was hypothesized that an
inhibitor (such as 8-hydroxyquinoline) would be capable of displacing the second BPA in
binding to Zn2+ (Figure 2.28).

Figure 2.27. Titration of 8-hydroxyquinoline into Zn(BPA)2 complex. BPA is a tridentate ligand that
binds Zn2+ in a 2 BPA: 1 Zn2+ ratio. The second BPA molecule interacting with Zn2+ is weakly bound,
thus when 8-hydroxyquinoline is injected, the second BPA molecule and a hydroxide ion are displaced
and 8-hydroxyquinoline binds.
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To avoid the potentially complicating issue of 8-hydroxyquinoline competing off the
second BPA molecule, 1:1 binding was forced by preparing the BPA-Zn2+ complex using a 1:1
ratio of BPA:Zn2+. Indeed, 1:1 binding of 8-hydroxyquinoline to BPA-Zn2+ was observed as 8hydroxyquinoline was titrated into a 1:1 BPA:Zn2+ solution with an n value of 0.976 ± 0.003 8HQ per BPA-Zn2+ complex (Figure 2.29). The raw ITC data did not show signs of the strongly
bound BPA being displaced by 8-hydroxyquinoline, nor did it show signs of 8-hydroxyquinoline
binding free rather than BPA-complexed Zn2+ because the n value of 0.976 ± 0.003 differed from
the n value of 1.98 ± 0.02 obtained for the titration of 8-hydroxyquinoline titration into Zn2+.
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Figure 2.29. Raw data (top panel) and binding isotherm (bottom panel) for titration of 10 mM
8-hydroxyquinoline into a solution containing 1 mM ZnCl2 and 1 mM BPA in MeOH:buffer mixture at
25 °C
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Titration experiments of 8-hydroxyquinoline into varying ratios of BPA:Zn2+ were
performed to determine if binding observed was 8-hydroxyquinoline binding to the binary
complex or just to free Zn2+. 8-hydroxyquinoline was titrated into a 1.11:1 BPA:Zn2+ solution
(Figure 2.30). The raw data appeared similar to that for titration into the 1:1 BPA:Zn2+ solution,
but the n value was 0.822 ± 0.009 8-hydroxyquinoline per total Zn2+. This n value suggests that
about 82% of the total Zn2+ were bound with only one BPA molecule and therefore were
available for binding by 8-hydroxyquinoline while the remaining 18% of the total Zn2+ were
bound with two BPA molecules and therefore not available for 8-hydroxyquinoline binding.
These numbers were close to the known molar ratios of 1.11:1 BPA:Zn2+ in the mixture. This
also suggests that 8-hydroxyquinoline was unable to displace the second BPA to bind Zn2+.
Titrations of 8-hydroxyquinoline into 1.5:1 BPA:Zn2+ and 2:1 BPA:Zn2+ solutions were
also performed. These experiments yielded n values of 0.62 ± 0.01 and 0.44 ± 0.04, respectively
(Figure 2.30). The decreasing n value with the increasing ratios of BPA:Zn2+ reflects the
decreasing presence of the Zn(BPA) complex and increasing presence of the Zn(BPA)2 complex.
It also suggests that not all Zn2+ were bound with two BPA molecules at the 2:1 BPA:Zn2+ ratio
despite the fact that twice as much BPA as Zn2+ was present, which can be explained by the weak
affinity of the second BPA molecule. The Zn(BPA) complexes were likely the species
coordinating to the 8-hydroxyquinoline. As the ratio of BPA:Zn2+ increased from 1:1 to 2:1, the
Ka value for 8-hydroxyquinoline binding also decreased, specifically by approximately 5-fold
from (1.57 ± 0.06) ×104 M-1 to (3.1 ± 0.7) × 103 M-1. This decrease of affinity was likely due to
the competition of the free BPA in the solution.
To conclude, for the BPA to be used as an HDAC structural mimetic, a 1:1 ratio of
BPA:Zn2+ was necessary and sufficient for creating a stable 1:1 complex capable of coordinating
to one molecule of 8-hydroxyquinoline.
Table 2.7. Thermodynamic parameters from ITC study of 8-hydroxyquinoline interaction with different
molar ratios of BPA:Zn2+*
Mimetic
ΔS°
Ka
ΔG°
ΔH°
TΔS°
n
(Ratio of
Kd (μM)
2+
4
-1
(8-HQ/BPA-Zn
)
(×
10
M
)
(kcal/mol)
(kcal/mol)
(kcal/mol)
(cal/mol⋅K)
2+
BPA:Zn )
0.976 ± 0.003
1.57 ± 0.06
64 ± 3
-5.73 ± 0.02
-10.35 ± 0.02
-15.52 ± 0.02
-4.630 ± 0.005
1:1
0.822 ± 0.009
1.43 ± 0.01
69.9 ± 0.7 -5.668 ± 0.006
-9.93 ± 0.05
-14.3 ± 0.2
-4.26 ± 0.05
1.11:1
0.62 ± 0.01
0.81 ± 0.03
124 ± 5
-5.33 ± 0.02
-9.1 ± 0.1
-12.5 ± 0.4
-3.7 ± 0.1
1.5:1
0.44 ± 0.04
0.31 ± 0.07
330 ± 80
-4.7 ± 0.1
-10 ± 2
-18 ± 6
-5 ± 2
2:1
*Titration of 10 mM 8-hydroxyquinoline into mixtures of BPA and ZnCl2 with ratios of BPA:Zn2+ ranging from 1
mM: 1 mM to 2 mM: 1 mM.

	
  

49	
  

	
  

Figure 2.30. Binding isotherms for titration of 8-hydroxyquinoline into different ratios of BPA:Zn2+ at
25 °C. Stars are 1:1 Zn2+:BPA, circles are 1:1.11 Zn2+:BPA, squares are 1:1.5 Zn2+:BPA, triangles are 1:2
Zn2+:BPA. As the ratio of BPA:Zn2+ increases, the n value and affinity decrease.
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The interaction of 8-hydroxyquinoline with the TPA-Zn2+ binary complex was also
studied using ITC. TPA and Zn2+ interactions were found in Section 2.2.3 to yield different n
values depending on injection order, thus the interaction of 8-hydroxyquinoline with two
different ratios of TPA:Zn2+ was investigated. An n value of 0.85 ± 0.06 Zn2+ per TPA was
determined when ZnCl2 was titrated into TPA. Based on these results, a 1.11:1 TPA:Zn2+ ratio
was selected for the titration of 8-hydroxyquinoline. When 8-hydroxyquinoline was injected into
the 1.11:1 TPA:Zn2+ solution, a very strong interaction was observed as indicated by the sharp
transition of the binding isotherm. The n value for this interaction was found to be 0.055 ± 0.007
8-hydroxyquinoline per TPA-complexed Zn2+. Such a small n value suggests that 8hydroxyquinoline did not bind the TPA-Zn2+ binary complex, rather it was binding to a very
small amount of free Zn2+ available in solution.
A different n value, 0.66 ± 0.02 TPA per Zn2+, was observed when TPA was titrated into
ZnCl2, which corresponded to 2 TPA bound per 3 Zn2+. Based on this stoichiometric ratio,
titrations of 8-hydoxyquinoline into a 0.66:1 TPA:ZnCl2 solution were performed and yielded an
n value of 0.98 ± 0.03 8-hydroxyquinoline per total Zn2+ in the 0.66:1 TPA:ZnCl2 solution and Ka
of (3.5 ± 0.8) × 105 M-1 (Figure 2.32). Because results from 8-hydroxyquinoline titration into
0.9:1 TPA:Zn2+ mixture suggest that 8-hydroxyquinoline did not bind the TPA-Zn2+ binary
complex, the current n value of 0.98 ± 0.03 8-hydroxyquinoline per total Zn2+ suggests that this
stoichiometry resulted from 8-hydroyquinoline binding free rather than TPA-bound Zn2+. When
the concentration was adjusted during curve fitting to reflect the amount of free Zn2+ in solution
and under the assumption 8-hydroxyquinoline was binding free and not TPA-bound Zn2+, the n
value was found to be 3 8-hydroxyquinoline per free Zn2+. The n value determined from titration
of 8-hydroxyquinoline into ZnCl2 was 1.98 ± 0.02 8-hydroxyquinoline per free Zn2+ with a Ka of
(2.0 ± 0.4) × 105 M-1. The n value for 8-hydroxyquinoline binding Zn2+ from the 8hydroxyquinoline into Zn2+ experiments was the experiment with the most reliable n value
because the exact amount of free Zn2+ in the 0.66 TPA: 1 Zn2+ remains unknown. However, it is
also possible that the n value observed for 8-hydroxyquinoline binding the free Zn2+ ions
available when TPA was present was higher than that for when TPA was not present as a result
of the presence of TPA affecting the binding of 8-hydroxyquinoline to free Zn2+. Additionally,
the hydroxide ions present in solution that typically compete to bind Zn2+ may preferentially bind
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the TPA-Zn2+ complex due to its neutral charge; this lack of competition for Zn2+ binding then
led to more 8-hydroxyquinoline molecules binding Zn2+.
TPA was shown to have a high affinity for Zn2+, with a Ka of (3 ± 1) × 105 M-1 from Zn2+
into TPA titration experiments and (7 ± 4) × 106 M-1 from TPA into Zn2+ titration experiments.
TPA binds Zn2+ very tightly. Based on the stoichiometric ratio obtained from 8-hydroxyquinoline
titration into TPA and Zn2+ mixtures of either 0.66:1 or 0.9:1 TPA:Zn2+ molar ratio, TPA binds
so tightly that the 8-hydroxyquinoline was not able to displace the TPA. Additionally, because
TPA is tetradentate, it does not leave adequate space for 8-hydroxyquinoline to coordinate Zn2+
in the TPA-Zn complex. Thus, 8-hydroxyquinoline was only able to bind whatever free Zn2+ was
available in solution (Figure 2.31). Based on these results it was concluded that the TPA-Zn
binary complex was not suitable as a HDAC structural mimetic.

Figure 2.31. Titration of 8-hydroxyquinoline into TPA-Zn2+ complex. TPA binds Zn2+ 1:1 with a very
high affinity greater than that of 8-hydroxyquinoline for Zn2+. TPA is tetradentate and does not leave
adequate space on Zn2+ for 8-hydroxyquinoline to bind while Zn2+ is complexed with TPA; thus when 8hydroxyquinoline is titrated into the TPA-Zn2+ complex, the only binding observed is of 8hydroxyquinoline binding to whatever small amount of free Zn2+ is available in solution.
Table 2.8. Thermodynamic parameters from ITC study of 8-hydroxyquinoline interaction with different
molar ratios of TPA:Zn2+*
Mimetic
n
Ka
ΔG°
ΔH°
ΔS°
Kd (μM)
(TPA:Zn2+)
(8-HQ/TPA-Zn2+) (× 105 M-1)
(kcal/mol)
(kcal/mol) (cal/mol*K)
1.11:1
0.055 ± 0.007
0.42 ± 0.07
24 ± 4
-6.29 ± 0.09
-9 ± 2
-8 ± 6
0.66:1
0.98 ± 0.03
3.5 ± 0.8
3.0 ± 0.7
-7.5 ± 0.1
-9.4 ± 0.1
-6 ± 1
*Titration of 10 mM 8-hydroxyquinoline into 1 mM ZnCl2 with 0.66 mM TPA or 1.11 mM TPA.

	
  

TΔS°
(kcal/mol)
-2 ± 2
-1.8 ± 0.2
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Figure 2.32. Raw data (top panel) and isotherm (bottom panel) for titration of 10 mM
8-hydroxyquinoline into 1 mM ZnCl2 and 1.11 mM TPA in MeOH:buffe mixture at 25 °C
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As explained in Section 2.2.5, TREN was determined to bind Zn2+ in a 1:1 stoichiometric
ratio but had a weaker affinity for Zn2+ in NEM buffer than in the MeOH:buffer mixture. ITC
experiments for 8-hydroxyquinoline binding to the TREN-Zn2+ binary complex were performed
with a mixture of TREN and ZnCl2 at 1.11:1 TREN:Zn2+ ratio to ensure that no free Zn2+ existed
in solution and that if 8-hydroxyquinoline binding was indeed observed, it was binding to
TREN-Zn2+ complex rather than free Zn2+. The binding isotherm (Figure 2.34) showed a
downward trend initially followed by an increasing trend. This suggests that 8-hydroxyquinoline
was displacing the TREN bound to Zn2+, forming a 8-hydroxyquinoline-Zn2+ binary complex
rather than the 8-hydroxyquinoline-Zn2+-TREN ternary complex. When the ITC data from the 8hydroxyquinoline into TREN-Zn2+ binary complex was analyzed, the n value was determined as
1.8 ± 0.2 8-hydroxyquinoline per total Zn2+ with a Ka of (1.2 ± 0.2) × 103 M-1. This n value was
similar to that of 8-hyroxyquinoline binding free Zn2+. The Ka was much smaller than that for 8hydroxyquinoline binding free Zn2+ due to the fact that 8-hydroxyquinoline must first displace
TREN in order to bind (Figure 2.33). Based on these results, TREN is not an acceptable ligand to
create an HDAC structural mimetic.

Figure 2.33. Titration of 8-hydroxyquinoline into TREN-Zn2+ complex. The TREN-Zn2+ complex is a 1:1
complex, but the affinity of TREN for Zn2+ is not greater than the affinity of 8-hydroxyquinoline for Zn2+.
TREN is tetradentate and when bound to Zn2+ does not leave adequate space on Zn2+ for
8-hydroxyquinoline to bind; thus, 8-hydroxyquinoline displaces the TREN in order to form a
Zn(8-hydroxyquinoline)2 complex.
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Figure 2.34. Raw data (top panel) and isotherm (bottom panel) for titration of 10 mM
8-hydroxyquinoline into 1 mM ZnCl2 and 1.11 mM TREN in the MeOH:buffer mixture at 25 °C
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Table 2.9. Thermodynamic parameters from ITC study of 8-hydroxyquinoline interaction with the 1.11:1
TREN:Zn2+ HDAC structural mimetic*
n
ΔG°
ΔH°
ΔS°
TΔS°
(8-HQ/ligandKa (M-1)
Kd (μM)
(kcal/mol)
(kcal/mol)
(cal/mol*K)
(kcal/mol)
Zn2+)
1.8 ± 0.2
1200 ± 200
800 ± 100 -4.22 ± 0.08
-2.8 ± 0.2
1±5
1.42 ± 0.09
*Titration of 10 mM 8-hydroxyquinoline into a mixture containing 1 mM ZnCl2 and 1.11 mM TREN.

2.3.2 Acetohydroxamic Acid interaction with HDAC structural mimetic
Suberoylanilide hydroxamic acid (SAHA) is an FDA-approved HDAC inhibitor used to
treat cutaneous T-cell lymphoma. The hydroxamic acid in SAHA functions as the zinc-binding
group, binding Zn2+ with the carbonyl oxygen and oxyanion. SAHA has poor aqueous solubility
and is insoluble in NEM buffer at pH 6.80. Thus, ITC experiments were only attempted in the
MeOH:buffer mixture. SAHA is soluble only up to 10 mM in the MeOH:buffer mixture. The
binding of SAHA to Zn2+ is weak, thus to favor binding in order to accurately extract binding
parameters, concentrations of SAHA higher than 10 mM would need to be used. Because only
the hydroxamic acid moiety of SAHA is involved in Zn2+ coordination, acetohydroxamic acid
(which contains the hydroxamic acid group and also offers good aqueous solubility) was used in
place of SAHA for titration into the chosen HDAC structural mimetic in both NEM buffer and
the MeOH:buffer mixture.

Figure 2.35. Suberoylanilide Hydroxamic Acid (SAHA) (left) and Acetohydroxamic Acid (AHA) (right).
Both molecules contain the same hydroxamic acid zinc-binding group, but acetohydroxamic acid lacks
the linker and surface recognition domain portions of SAHA.

The Jin lab had previously investigated the interaction of AHA with ZnCl2 in both
solvent systems and found that a substantial heat was still present at the last few injections of the
titration of AHA into Zn2+.29 However, the control experiment of titrating AHA into solvent only
did not show a substantial heat in either solvent system, suggesting that at the concentrations
used (up to 50 mM AHA), binding of AHA to Zn2+ was not complete at the last injections of
AHA into Zn2+. Further increasing of the concentration of AHA as a titrant to favor binding
would generate heat powers that exceed the limit of the VP-ITC. With the incomplete binding
isotherm and the low c value (c = nKa[cell]) of less than 1 (optimal window of c is 1-1000,
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preferably 5-500), curve fitting did not result in meaningful n values (as any n value of 0.5 or
below fit the data equally well). An n value of ≤ 0.5 AHA per Zn2+ suggests ≥ 2 Zn2+ ions bound
per AHA, an unlikely scenario as the hydroxamic acid group can only chelate one metal ion.
Additionally, it was also believed that the difficulty in extracting meaningful binding parameters
(particularly the n value) resulted from the inability to identify the proper control heat to subtract.
The control heat may be due to the electrostatic effect of Zn2+, whether as free or AHA-bound
Zn2+, on AHA when AHA is injected into the cell. An n value of at least one or two AHA are
expected to bind per Zn2+ in the complex between AHA and Zn2+. To obtain an estimate of the Ka
and ΔH° values, curve fitting of the binding isotherm was carried out by fixing n at a value of
0.5 and by allowing all parameters to float with each iteration of the fit.
Titrations of 50 mM AHA into a mixture containing 5 mM ZnCl2 and 5 mM BPA were
performed in NEM buffer and the MeOH:buffer mixture. Experiments in both solvent systems
were indicative of AHA binding the BPA-Zn2+ complex.
These titrations contained the same control heat in both solvent systems and a proper
control was not identified for the titration of AHA into the BPA-Zn2+ complex (Figure 2.36). The
closest control would be injection of AHA into an AHA and ZnCl2 mixture with excess amount
of AHA. As can be seen in Figure 2.36, the heat at the last injections was substantial and the
isotherm did not plateau as it would when binding is complete. This control heat was also
observed in the experiments performed previously in the Jin lab looking at the interaction of
AHA with free Zn2+.29 Analysis of the data were performed by allowing all parameters to vary
with iterations of the fit and also by fixing the n value at 0.5 to demonstrate how the other
parameters change depending whether n is fixed or allowed to vary. Even when n was allowed to
vary, no n value above 0.5 resulted from the curve fitting. The Ka value varied substantially
depending on the n value. Again, the inability to find a unique set of n, Ka, and ΔH° parameters
lies in the c value being outside the optimal window (1-1000). This is due to weak affinity and
the sensitivity of the curve fitting to the control heat when a perfect control has yet to be
identified. Though Zn2+ is fully bound with AHA molecules, it may still exert an electrostatic
effect on the AHA being injected into the mixture, adding additional heat effect to the heat of
binding. Until a proper control is found, the data will not offer much insight into the contribution
of Zn2+-binding to the overall binding of acetohydroxamic inhibitors to HDAC. Experiments at a
higher pH, specifically at pH 7.25, are being explored to increase the binding affinity (higher pH
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promotes deprotonation of the alcohol thus less energetic cost due to deprotonation before Zn2+
binding) thereby increasing the accuracy of the resulting binding parameters. A pH of 7.25 is the
highest pH possible in NEM buffer for preparing a 1 mM ZnCl2 solution without Zn(OH)2
precipitation occurring.
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Figure 2.36. Raw Data (top panel) and isotherm (bottom panel) for titration of 50 mM AHA into 5 mM
Zn-BPA in NEM buffer at 25 °C. After binding is complete a substantial heat remains, making it difficult
to fit the data and also resulting in the data fitting a variety of n values under 0.5.
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Table 2.10. Thermodynamic parameters from ITC study of AHA interaction with BPA-Zn2+*
n
Ka (M-1)
(AHA/BPA-Zn2+)
NEM
0.4 ± 0.1
500 ± 200
Fixed at 0.5
600 ± 200
MeOH:Buffer
0.4 ± 0.1
400 ± 200
Fixed at 0.5
600 ± 40
*Titration of 50 mM AHA into 5 mM BPA-Zn2+
Solvent

Kd (μM)
2400 ± 1200
1900 ± 700
3000 ± 2000
1700 ± 100

ΔG°
(kcal/mol)
-3.6 ± 0.3
-3.7 ± 0.2
-3.5 ± 0.4
-3.80 ± 0.04

ΔH°

ΔS°

(kcal/mol)

(cal/mol⋅K)

-3 ± 2
-2.2 ± 0.4
-6 ± 4
-2 ± 1

0.9 ± 7
5±2
-7 ± 14
3.0 ± 0.5

TΔS°
(kcal/mol)
0.3 ± 2
1.6 ± 0.6
-2 ± 4
2±1

The goal of this project was to develop an HDAC active site structural mimetic to use in
ITC studies for interaction with different HDAC inhibitors in order to gain insight into the
energetic contribution of inhibitor active site zinc binding to the overall interaction with HDAC.
Requirements for the ligand as part of the structural mimetic were set to include binding Zn2+ in a
1:1 ratio with a very high affinity such that when inhibitor was introduced the ligand would not
dissociate from Zn2+, and the ligand-Zn2+ binary complex must be able to bind inhibitor via Zn2+
without the ligand being displaced. Five ligands – NTA, TPA, BPA, TREN and DA2Im – were
assessed in their suitability in creating an HDAC structural mimetic. Based on the results of ITC
studies of each ligand interacting with Zn2+, BPA, TPA, and TREN were selected for preliminary
screening with an inhibitor and strong metal chelator 8-hydroxyquinoline.
Experiments between 8-hydroxyquinoline and TREN-Zn2+ complex revealed that TREN
was displaced from Zn2+ by 8-hydroxyquinoline, resulting in the formation of a complex, Zn(8hydroxyquinoline)2. The ITC results for 8-hydroxyquinoline interaction with TPA-Zn2+ binary
complex showed that TPA was not displaced by 8-hydroxyquinoline nor was 8hydroxyquinoline able to bind the Zn2+ in the TPA-Zn2+ complex. Evidently, TPA, which is
tetradentate, did not leave adequate coordination sites on the TPA-bound Zn2+ for 8hydroxyquinoline binding. The only binding observed in ITC was due to 8-hydroxyquinoline
binding a residual amount of free Zn2+ ions with the same affinity as observed for 8hydroxyquinoline injection into free Zn2+. BPA, which is tridentate, was the only ligand that not
only remained bound to Zn2+ upon 8-hydroxyquinoline injection, but also left sufficient
coordination sites for 8-hydroxyquinoline coordination.
ITC experiments were also performed for BPA-Zn2+ complex with another HDAC
inhibitor, AHA, in which a solution of AHA was titrated into a 1:1 solution of the BPA-Zn2+
complex. These experiments were indicative of AHA binding the BPA-Zn2+ complex, but with
the affinity too weak to be accurately determined in either the buffer or MeOH:buffer mixture at
pH 6.80. With such a weak affinity and thus too small a c value, infinite combinations of n, Ka,
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and ΔH° values were found to fit the binding isotherm but none provided a reasonable n value of
at least 1 AHA per Zn2+. To obtain an accurate set of binding parameters, either higher
concentrations of titrant and titrate (thus increasing the c value) or solution conditions promoting
stronger binding are required to determine the binding parameters accurately. Further increasing
of AHA and Zn2+ concentration not only is unrealistic due to limited Zn2+ solubility in solution,
but also it will further increase the heat that was already at the upper limit of the VP-ITC.
However, increasing the pH to promote deprotonation of the AHA hydroxamic acid and thus
increase the affinity of AHA for Zn2+ may be a viable option. Future directions for this project
include 1.) finding an appropriate control to subtract from the AHA experiments such that they
can be properly analyzed and 2.) expanding the study to other potential HDAC inhibitors’ and
their zinc binding groups. Additionally, future studies would also investigate the interaction of
SAHA with the HDAC structural mimetic.
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2.4 Computational Studies of HDAC structural mimetic (BPA-Zn2+) with
8-hydroxyquinoline
Computational calculations of the entire HDAC enzyme are time consuming due to its
large size. The ability to glean valuable information regarding the enzyme’s catalytic activity
without consideration of the entire structure is important. Vanommeslaeghe and coworkers
performed a DFT-based ranking of zinc-binding groups in HDAC inhibitors using an empty
catalytic core model for HDAC, determining that the most effective inhibitors are bidentate
chelators with high chemical hardness.30 Preliminary computational calculations were performed
to complement the results of the ITC experiments studying the interaction of BPA with Zn2+ and
the interaction of 8-hydroxyquinoline with the BPA-Zn2+ binary complex. These calculations
provide useful information that contributes to a better understanding of the overall interaction
between BPA and Zn2+ to form the BPA-Zn2+ binary complex as well as the interaction of the
BPA-Zn2+ complex with 8-hydroxyquinoline.
In this work, relevant structural parameters and the complexation energies of the BPAZn2+ complexed with the HDAC inhibitor 8-hydroxyquinoline were investigated in various
solvents versus in vacuo. A conformational transition of the BPA ligand was also studied using
the intrinsic reaction coordinate calculation, which provides information about the flexibility and
intrinsic movement of the BPA molecule. These computational calculations yield insight into the
binding of 8-hydroxyquinoline to the BPA-Zn2+ complex through information about bond lengths
and complexation energy.
2.4.1 Computational Methods
Preliminary Ab initio calculations were performed with the Gaussian 2009 program
package.31 All geometry optimizations, frequency calculations, IRC calculations and BSSEcorrected complexation energy calculations were conducted at the BLYP/3-21g level of theory.
Complexation energies were calculated by subtracting the individually optimized and calculated
energies of the BPA-Zn2+ complex and inhibitors from the energy of the optimized complex.
Basis set effects were explored using the larger cc-PVDZ basis set.
2.4.2 Bis(2-picolyl)amine optimization and frequencies
Bis(2-picolyl)amine (BPA) (Figure 2.38) was optimized at both the BLYP level of theory with
the 3-21g and cc-PVDZ basis sets. When optimized, the three nitrogens in the BPA are oriented
to allow for intramolecular hydrogen bonding to stabilize the structure. The bonds between the
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central nitrogen and pyridine rings are flexible and rotate to accommodate the intramolecular
hydrogen bonding. The distances between each nitrogen in the optimized BPA structure are
reported (Table 2.11). The bond distance between each pyridine nitrogen and the central nitrogen
are equal, but for the PVDZ optimized structure has slightly longer bonds to obtain a slightly
more stable structure.

Figure 2.38. Structure of Bis(2-picolyl)amine
Table 2.11. Structural parameters from the optimized BPA

Basis Set

BLYP/3-21g
N1-N2* N3-N2
Lengths (Å) 2.725
2.725

N1-N3
4.188

N1-H
2.211

N3-H
2.211

BLYP/cc-PVDZ
N1-N2 N3-N2 N1-N3
2.801 2.802 4.547

N1-H
2.352

N3-H
2.354

*Numerical subscripts in table correspond to those in Figure 2.38

2.4.3

Bis(2-picolyl)amine Intrinsic Reaction Coordinate calculation

Improved understanding of the preferred conformation of BPA can be obtained from the
evolution of relevant geometrical parameters along the reaction path. The BPA molecule can
exist in many different conformations, which affect its binding to the Zn2+ ion. One transition to
consider is the central nitrogen transitioning from below to above the two pyridine rings. As
shown in Figure 2.28B, the transition state for this process is a completely planar BPA molecule.

	
  

63	
  

	
  
A. BPA minimum 1

B. Planar BPA Transition State

C. BPA Minimum 2

Figure 2.38. Input structures for IRC calculation

The planar BPA was confirmed as a transition state by a QST3 calculation and also by
the presence of an imaginary frequency. The Intrinsic Reaction Coordinate (IRC) calculation
effectively connects the two minima (Figures 2.39A and 2.39C) of this process through the
transition state as a maximum. The IRC calculation is done in vacuo and provides insight into the
energy required for the transition between the different conformations. The energy profile
demonstrates that a small amount of energy is required for this conformational change (Figure
2.39). The energy difference between the transition state and each minimum is the activation
energy, 1.65 kcal/mol. By taking the first derivative of the relative energy, the force required for
the transition is obtained. A plot of force versus the reaction coordinate yields a force profile
(Figure 2.39).
Two critical points, a minimum and a maximum, are observed in the force profile. The
force profile demonstrates that a small force is required for this conformational change to
proceed. It is important to recognize that the IRC calculation was done in the gas phase. To
obtain the activation energy in solvent, the transition state and minima were optimized in the
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solvent and the difference between their energies was taken. The activation energy in each
solvent was compared with the activation energy in vacuo by calculating the percent difference
(Table 2.12). The activation energy is much greater in both solvents than in vacuo due to the
additional energy involved in desolvation and solvation processes.
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Figure 2.39. BLYP/3-21g energy profile for BPA (left) and BPA reaction force profile (right)
Table 2.12. Activation Energies in solvent and gas phase

Vacuum
Aqueous
Acetonitrile

Activation Energy
(kcal/mol)
1.65
2.89
2.85

% difference

54.4 %
53.2 %

2.4.4 Bis(2-picolyl)amine-Zn2+ complex optimization
The optimized BPA structure was edited to be complexed with Zn2+ and the resulting BPA-Zn2+
complex was then optimized at both levels of theory. The three nitrogens in BPA are used to
strongly complex Zn2+ in such a way that two five-membered rings result. Relevant structural
parameters were extracted from the optimized structure (Table 2.13). The two basis sets yielded
similar results.The larger cc-PVDZ basis set yielded a more symmetrical BPA complex, with the
pyridine nitrogens the same distance from Zn2+ and with the same bond angle. The 3-21g
optimized BPA-Zn2+ complex had BPA contorted about the Zn2+ with smaller bond angles than
that of the cc-PVDZ optimized structure. The 3-21g optimized complex does not accommodate
the restricted bond angles of the pyridines, resulting in a cramped structure with a large amount
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of steric strain. The total energy of the cc-PVDZ complex is lower than that of the 3-21g
optimized complex, indicating that the higher degree of symmetry results in a more stable
complex by reducing steric strain (Table 2.14).

Figure 2.40. BPA-Zn2+ Complex
Table 2.13. Structural parameters of optimized BPA-Zn2+

Basis Set
Blyp/3-21g
Blyp/cc-PVDZ
Blyp/3-21g
Blyp/cc-PVDZ

Bond Lengths (Å)
N1-N2 N3-N2 N1-N3 N1-Zn N3-Zn N2-Zn
2.818 2.781
3.518 1.854 1.853
1.930
2.821 2.821
3.893 1.959 1.959
2.096
Bond Angles (°)
C4-N1-Zn
C7-N3-Zn
C5-N2-C6
109.0
105.3
114.4
110.6
110.6
118.9

*Numbers correspond to numbering in Figure 2.40
Table 2.14. Total Energies of BPA-Zn2+ based on basis set

Basis Set
Blyp/3-21g
Blyp/cc-PVDZ

Energy with ZPE (kcal/mol)
-1.503 × 106
-1.511 × 106

2.4.5 HDAC active site structural mimetic interaction with 8-hydroxyquinoline
The optimized BPA-Zn2+ complex was edited to include the HDAC inhibitor 8hydroxyquinoline (8-HQ), and optimized at the blyp/3-21g level of theory. Optimization of
BPA-Zn-8HQ was not completely successful. The optimization went through 24 iterations until
an error occurred. Inspection of the optimization plot revealed that the optimization was nearly
complete, as the total energy had begun plateauing at iteration 15; thus, in the interest of time the
project was continued with the nearly optimized BPA-Zn-8-hydroxyquinoline complex (Figure
2.41).
8-hydroxyquinoline binds the BPA-Zn2+ binary complex in a perpendicular angle to the
BPA plane. The oxygen and nitrogen of bidentate 8-hydroxyquinoline are used to chelate the
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Zn2+. The binding of 8-hydroxyquinoline has some steric hindrance due to the bulky, conjugated
ring system of 8-hydroxyquinoline. However, the conjugated ring system allows for the electron
density to be more centralized at the Zn2+ binding sites, resulting in 8-hydroxyquinoline having a
high affinity for the BPA-Zn complex. The 8-hydroxyquinoline is deprotonated and the BPAZn2+-8-hydroxyquinoline complex has a charge of +1

Figure 2.41. 8-hydroxyquinoline complexed with BPA-Zn2+ binary complex. Shown is BPA-Zn2+-8hydroxyquinoline complex (left) and the optimized BPA-Zn2+-8-hydroxyquinoline structure (right).

Relevant structural parameters were obtained from the optimized BPA- Zn2+-8hydroxyquinoline complex in different environments (Table 2.15). Although the energies of the
complexes changed, the bond lengths of the BPA- Zn2+-8-hydroxyquinoline ternary complex did
not change in the different environments. Compared to the 8-hydroxyquinoline phenol oxygen,
the 8-hydroxyquinoline nitrogen had a longer bond distance of 2.002 Å. The pyridine nitrogen on
8-hydroxyquinoline is a part of the ring, whereas the oxygen is bonded to the ring, allowing it to
get closer to the BPA- Zn2+ complex and form a shorter bond (Figure 2.41). The formation of the
BPA- Zn2+-8-hydroxyquinoline ternary complex must overcome steric strain due to the
conjugated ring system of 8-hydroxyquinoline.
Table 2.15. Bond lengths of BPA- Zn2+-8-HQ complexes

Bond Lengths (Å)
8-HQ-Zn
BPA-Zn2+
O1-Zn
N4-Zn
O1-Zn
N4-Zn
1.896
2.002
1.977
1.962
2+

	
  

O1-Zn
2.296
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Table 2.16. Complexation Energy for BPA- Zn2+ with 8-hydroxyquinoline

Environment
Vacuum
Aqueous
Acetonitrile

BPA-Zn2+-AHA
Complexation
BSSE Corrected
Energy
Complexation
(kcal/mol)
Energy (kcal/mol)
-543.16
-463.27
-162.55
N/A
-168.88
N/A

BPA-Zn2+-8-hydroxyquinoline
Complexation
BSSE Corrected
Energy
Complexation
(kcal/mol)
Energy (kcal/mol)
-267.697
-240.81
-79.014
N/A
-82.53
N/A

The complexation energies in each environment (Table 2.16) demonstrate how the
formation of the complex is less favorable in solvent. The complexation energy is significantly
less in vacuo than in either solvent. The total energy of each complex is comparable in each
environment, but the BPA-Zn and 8-hydroxyquinoline are individually more stabilized in solvent
by the solvent interactions than in vacuo; thus, bringing the two together to form the complex in
solvent is more costly in terms of energy as there are additional interactions that must be
disrupted for complexation to occur. Each individual part – BPA-Zn2+ and 8-hydroxyquinoline –
must be desolvated for the complex to form, and after the complex forms, the complex is
subsequently solvated. These solvation and desolvation processes make complexation
energetically less favorable in solvent than in vacuo.
The BPA-Zn2+-8-HQ complex has the smallest complexation energy in vacuo and the
largest in water. Water is a polar protic solvent, thus the anions in the inhibitor are more solvated
in water than acetonitrile and require more energy to be desolvated. Acetonitrile is a polar aprotic
solvent; thus, it solvates the positively charged zinc more than water will. Based on these results,
the solvation of 8-hydroxyquinoline has a more significant effect on the complexation energies
than the solvation of zinc.

	
  

68	
  

	
  
2.5 Issues with acetonitrile as solvent for ITC
The inconsistency of the ITC results from this work with those of Canary and coworker’s
potentiometric titrations were attributed to the fact that the potentiometric study was performed
in water and with perchlorate as the counter ion which does not compete with the ligands for
Zn2+ binding. In an attempt to gain insight into the binding of the ligands to Zn2+ without any
competition from Cl- ions or even water and hydroxide ions, ITC experiments were performed
for ligands interacting with Zn2+ using (ZnBF4)26H2O as the source of Zn2+ ion, BF4- replacing
Cl- as the counterion, and acetonitrile as the solvent. Experiments in acetonitrile were plagued
with poor reproducibility. In the raw ITC data, small endothermic heat was present toward the
end of an exothermic peak and these endothermic peaks became more prominent at the end of
the titration (Figure 2.42). As these endothermic peaks did not seem to be proportional to the
extent of binding, unless they were subtracted the binding isotherm could not be deconvoluted
(fit to a simple binding model) to yield binding parameters for the interaction between ligand and
Zn2+ (Figure 2.43). It was hypothesized that residual water in the solvent was the cause of the
poor reproducibility. Kano and coworkers reported that addition of a small amount of water to
acetonitrile when used as the solvent in ITC experiments, resulted in drastic change to the shape
of individual peaks and also to the overall binding isotherm.32 Specifically, Kano and coworkers
reported that an endothermic heat process resulted in ITC experiments done in acetonitrile when
0.5% water was present, but was significantly decreased when there was 0.1% water.32 To
remove residual water, acetonitrile from a solvent purification system was used and the ITC cells
were thoroughly dried prior to setting up each experiment. However, the water introduced from
the (ZnBF4)26H2O remained. Raw data and the binding isotherm from each experiment
remained consistently irreproducible. There have been other attempts by the Jin lab to conduct
ITC studies in other organic solvents, such as methanol, but the same issues with reproducibility
resulting from water contamination have been encountered. Until a better method of eliminating
all water from the system is identified, experiments done in organic solvents will continue to be
irreproducible and difficult to analyze.
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Figure 2.42. Raw data for titration of BPA into Zn(BF4)2 in acetonitrile. The first five peaks correspond
to BPA binding Zn2+ and are exothermic, but all endothermic peaks after the first five peaks are due to the
presence of a small amount of water.

	
  

70	
  

	
  

Figure 2.43. Overlay of isotherm for titrations done with acetonitrile as solvent. Triangles are for the
titration of BPA into ZnBF4 in acetonitrile, squares are the control run of titration of BPA into
acetonitrile. The trend seen for the control run was also present in the titration of BPA into Zn(BF4)2,
making it difficult to analyze the data since the control cannot be easily subtracted.
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Chapter 3. Studies of interaction of tetracycline, minocycline, and tigecycline with Zn2+ and
Ca2+
3.1 Introduction to matrix metalloproteinases and their inhibition
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases
involved in physiological and pathophysiological processes such as angiogenesis, inflammation
and embryogenesis. First discovered in 1962 by Gross and Lapiere, MMPs have become of
interest as a target for various diseases such as arthritis, cancer and aortic aneurysm.33 MMPs
proteolyze several proteins of the extracellular matrix and their increased activity contribute to
the pathogenesis of several cardiovascular diseases; thus, inhibition of MMPs is a growing
therapeutic aim to treat various cardiovascular diseases. MMPs are referred to numerically from
1-28 and have traditionally been grouped according to their extracellular matrix substrates,
primary structure or subcellular localization as gelatinases (MMP-2 and -9), collagenases (MMP1, -8, and -13), stromelysins (MMP-3 and -10), matrilysins (MMP-7 and -26), metalloelastases
(MMP-12) and membrane-type MMPs (MMP-14-16 and -23-25).33
MMPs contain a catalytic Zn2+ that is coordinated by three histidines in the active site
(Figure 3.1). Synthesized as zymogens, MMPs have an autoinhibitory hydrophobic propeptide
that binds Zn2+ with a cysteine thiol and shields the Zn2+ ion in the catalytic domain from
interacting with substrates. The MMPs become activated after a “cysteine switch” in which the
propeptide cysteine dissociates via proteolysis or conformational changes of the zymogen
induced by oxidizing agents.33

Figure 3.1. Active site of MMP-14. Zinc shown in grey as a sphere, is coordinated by three hisitidines
shown in stick form. Image was generated in PyMol using PDB 1BUV.
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MMPs degrade several extracellular matrix proteins and play a key role in embryonic heart
development and in adaptive vascular remodeling during exercise and pregnancy.33 MMPmediated proteolysis of the extracellular matrix contributes to tumor invasion as well.34 MMP
activity is elevated in cardiovascular inflammatory disorders such as Kawasaki disease and
Chagasic cardiomyopathy. During inflammatory mediated connective tissue breakdown, MMPs
work in combination with serine proteinases to bias the proteinase-antiproteinase balance toward
destruction of the extracellular matrix and basement membranes.35 MMP activity is intrinsically
regulated by phosphorylation, glutathiolation and tissue inhibitors of metalloproteinases
(TIMPs).33
Various zinc binding groups have been explored as potential MMP inhibitors, such as
cyclic peptides and hydroxamic acids, but issues with non-selectivity and susceptibility to
metabolism have prevented further progress. Chemically modified tetracyclines have previously
been shown to function as effective inhibitors of zinc matrix metalloproteinases.35 Golub and
coworkers reported the ability of tetracyclines to inhibit MMP activity via their ability to chelate
the catalytic Zn2+ ion independently of their antimicrobial properties in 1984.36 It has been
assumed that inhibition of MMPs is dependent on the inhibitor’s ability to chelate the catalytic
Zn2+ ion, but some studies have suggested that the inhibitory activity is a result of the inhibitor
binding to structural metals such as Ca2+ and Zn2+ rather than the active site Zn2+.34 This
hypothesis is supported by results showing that MMP inhibition can be reversed by adding
millimolar amounts of Ca2+ or micromolar amounts of Zn2+, as well as a study demonstrating that
the MMP inhibitor doxycycline binds MMP-7 near structural Ca2+ and Zn2+ ions rather than the
active site Zn2+.37
The tetracyclines are composed of a four-fused ring core and different side groups have
been added to the tetracycline core in order to obtain more potent analogues (Figure 3.2). The
dimethylamino group present on all tetracyclines is required for antimicrobial activity.34 The
keto-enol moiety on the lower portion of tetracyclines is used to bind divalent metal ions such as
Ca2+ and Zn2+. The affinity of tetracyclines for different metal ions depends on the specific
member of the tetracyclines and the metal ion involved as well as pH. In general, a given
tetracycline member has greatest affinity for Cu2+ and lowest affinity for Ca2+ out of the
physiological divalent metals.
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Figure 3.2. Structures of tetracycline (top left), minocycline (top right) and tigecycline (bottom). The
tetracyclines are all composed of a four fused ring core to which different side groups are attached in
order to obtain more effective analogues.

Due to their abilities in chelating metal ions, the tetracyclines are potential inhibitors for MMPs.
However, administering antibiotics for non-bacterial based disease is a concern as it has the
potential to further antibacterial resistance. Chemically modified tetracyclines that retain the
ability to inhibit MMPs but are devoid of antimicrobial properties have been synthesized to
address this issue.35 Additionally, minocycline and doxycycline have both been shown to inhibit
MMPs at plasma levels lower than necessary for antimicrobial effect.33 Understanding the
contribution of the interaction between the tetracyclines and the structural calcium and zinc ions
to the overall enzyme-inhibitor interaction can potentially aid in the design of more effective
MMP inhibitors.
3.2 ITC studies of three members of the tetracycline family interacting with Zn2+
The binding interactions between tetracycline (TC), minocycline (MC), and tigecycline
(TgC) with Zn2+ were studied using a VP-ITC microcalorimeter at 25 °C. ITC studies were
performed in both 50 mM NEM buffer (0.15 M NaCl, pH 6.80) and 50 mM Tris (0.10 M NaCl,
pH 7.50), which will from here on out be referred to as NEM buffer and Tris buffer, respectively.
Solutions of 5 mM Zn2+ were titrated into 0.5 mM solutions of each of the three compounds.
Average binding parameters for each antibiotic’s interaction with Zn2+ are listed in Table 3.1. To
determine the heat due to processes other than those directly associated with the binding process,
control experiments of Zn2+ titration into each buffer were carried out. The resulting isotherms
proved that there was negligible Zn2+ dilution heat thus no control heat was subtracted. The raw
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ITC data and binding isotherm for a representative experiment is shown below in Figures 3.3,
3.4, and 3.5 for each tetracycline, minocycline and tigecycline, respectively.
All binding isotherms were fit to the one-set-of-sites model to yield the physical
parameters of the interaction. At pH 6.80, tetracycline had the weakest affinity for Zn2+, with a Ka
of (8 ± 3) × 103 M-1, while tigecycline and minocycline had 2.4- and 4.2-fold stronger affinity for
Zn2+ as compared to tetracycline. The n values for both minocycline and tigecycline interacting
with Zn2+ at pH 6.80 were similar, being 0.43 ± 0.08 and 0.39 ± 0.03 Zn2+ per antibiotic,
respectively. This corresponds to 1 Zn2+ bound by 2-3 antibiotic molecules. However,
tetracycline at pH 6.80 had an n value of 0.64 ± 0.08 Zn2+ per tetracycline, corresponding to two
Zn2+ ions shared by three tetracycline molecules. The binding of minocycline and tigecycline to
Zn2+ at pH 6.80 resulted in an entropic loss and the interaction is therefore enthalpically driven.
Binding of tetracycline to Zn2+ at pH 6.80 was accompanied with an entropic gain and is
therefore both enthalpically and entropically driven.
Table 3.1. Thermodynamic parameters from ITC study of tetracycline, minocycline and tigecycline with
Zn2+ in NEM buffer pH 6.80 at 25 °C.
AB
TC
MC
TgC

	
  

n
(Zn2+/AB)
0.64 ± 0.08
0.43 ± 0.08
0.39 ± 0.03

Ka
(× 104 M-1)
0.8 ± 0.3
3.4 ± 0.5
1.91 ± 0.07

Kd
(μM)
130 ± 40
30 ± 5
52 ± 2

ΔG°
(kcal/mol)
-5.3 ± 0.2
-6.17 ± 0.09
-5.84 ± 0.02

ΔH°
(kcal/mol)
-0.96 ± 0.08
-1.99 ± 0.07
-2.16 ± 0.05

ΔS°
(cal/mol⋅K)
1 ± 0.4
-1.7 ± 0.3
-2.6 ± 0.2

TΔS°
(kcal/mol)
4.4 ± 0.3
-4.2 ± 0.1
3.68 ± 0.07
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Figure 3.3. Raw data (top panel) and isotherm (bottom panel) for titration of 5 mM ZnCl2 into 0.5 mM
tetracycline in NEM buffer pH 6.80 at 25 °C.
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Figure 3.4. Raw data (top panel) and isotherm (bottom panel) for titration of 5 mM ZnCl2 into 0.5 mM
minocycline in NEM buffer pH 6.80 at 25 °C.
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Figure 3.5. Raw data (top panel) and isotherm (bottom panel) for titration of 5 mM ZnCl2 into 0.5 mM
tigecycline in NEM buffer pH 6.80 at 25 °C.
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Binding isotherms were also obtained in 50 mM Tris buffer (0.1 M NaCl pH 7.50) and
were fit to a one-set of sites model (Figure 3.6). At this pH, tetracycline once again had the
weakest affinity among the three tetracyclines for Zn2+ with a Ka of (1.490 ± 0.006) × 104 M-1
while tigecycline and minocycline had 2- and 4-fold as strong an affinity for Zn2+ as tetracycline,
respectively. Minocycline and tigecycline did not exhibit pH-dependent binding to Zn2+ and
binding was enthalpically driven and resulted in entropic loss. For all three antibiotics, their
affinity for Zn2+ increased one-fold from pH 6.80 to 7.50. Stoichiometry was also similar at the
two pH values for minocycline and tigecycline, with the n value for minocycline being 0.450 ±
0.008 at pH 7.50 and 0.43 ± 0.08 at pH 6.80, and the n value for tigecycline being 0.44 ± 0.04 at
pH 7.50 and 0.39 ± 0.03 pH 6.80. These n values correspond to 2-3 antibiotics sharing one Zn2+
ion. Tetracycline demonstrated pH-dependent binding stoichiometry to Zn2+ as the n value was
0.515 ± 0.007 at pH 7.50 and 0.64 ± 0.08 at pH 6.80, corresponding to two tetracycline
molecules sharing one Zn2+ ion at pH 7.50 but three tetracycline molecules sharing two Zn2+ ions
at pH 6.80. While tetracycline binding to Zn2+ transitioned from the formation of a 2 Zn2+: 3 TC
complex at pH 6.80 to the 1 Zn2+:2 TC complex at pH 7.50, its binding also transitioned from
being both enthalpically and entropically driven at pH 6.80 to only enthalpically driven at pH
7.50 as is the case for minocycline and tigecycline at both pH values. The shift in the enthalpic
and entropic contribution to the binding event involving tetracycline is consistent with the shift
in the binding mode from pH 6.80 to 7.50.
Table 3.2. Thermodynamic parameters from ITC study of tetracycline, minocycline and tigecycline with
Zn2+ in Tris buffer pH 7.50 at 25 °C.
n
Ka
Kd
ΔG°
(Zn2+/AB)
(× 104 M-1)
(μM)
(kcal/mol)
TC
0.515 ± 0.007
1.490 ± 0.006
67 ± 3
-5.69 ± 0.03
MC 0.450 ± 0.008
6.6 ± 0.1
15.1 ± 0.2 -6.580 ± 0.009
TgC
0.44 ± 0.04
4.0 ± 0.9
26 ± 6
-6.3 ± 0.1
*AB stands for antibiotic. Titration of 5 mM ZnCl2 into 0.5 mM AB.
AB

	
  

ΔH°
(kcal/mol)
-11.9 ± 0.3
-16.00 ± 0.04
-15 ± 1

ΔS°
(cal/mol⋅K)
-36 ± 15
-31.7 ± 0.2
-29 ± 5

TΔS°
(kcal/mol)
-6.2 ± 0.3
-9.45 ± 0.03
-9 ± 1
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Figure 3.6. Raw data (top panel) and isotherm (bottom panel) for titration of 5 mM ZnCl2 into 0.5 mM
tetracycline in Tris buffer pH 7.50 at 25 °C.
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3.3 UV-Vis Studies of three members of the tetracycline family interacting with Zn2+
The binding stoichiometries of tetracycline, minocycline, and tigecycline were also
determined using UV-Vis spectroscopy with the data analyzed by Job’s method.38 Studies were
done in two different buffers: 50 mM Tris buffer (0.1 M NaCl, pH 7.50) and 50 mM NEM buffer
(0.150 M NaCl, pH 6.80). Experiments were performed by combining different volumetric ratios
of 0.6 mM ZnCl2 and 0.6 mM antibiotic to a total volume of 100 μL, always ensuring that the
total concentration of the two interacting components and the ionic strength remained constant as
Job’s method requires. Absorbance measurements were taken at the maximum wavelength of
absorbance for the free antiobiotic and the antibiotic-Zn2+ complex. The molar absorptivity of
each antibiotic was calculated for each experiment by using Beer’s Law based on the absorbance
reading taken on a sample of pure antibiotic. The concentration of the complex formed at a given
molar fraction has been shown to be proportional to the observed absorbance for mixture of the
metal ion and the antibiotic (Aobs) minus the absorbance of the free antibiotic, which is the
product of the path length (b) and molar absorptivity (ε) and concentration of the free antibiotic
in each sample [AB]:
complex = A!"# − AB ∗ b ∗ ε

(1)

The above term proportional to the concentration of complex was plotted as a function of the
molar fraction of Zn2+ (out of the total moles of Zn2+ and antibiotic), which yielded the Job’s plot.
The maxima or minima in the Job’s plot correspond to the molar fraction of the two interacting
components (Zn2+ and antibiotic) in the complex formed. A representative Job’s Plot is shown
below for minocycline interaction with Zn2+ at pH 6.80. Once the molar fraction of Zn2+ for the
complex is determined, it is possible to calculate the stoichiometric ratio of Zn2+ to the antibiotic
in the complex using equation (2).
!"#$  !"#$%&'(  !!!

Stoichiometric  molar  ratio = !!!"#$  !"#$%&'(  !!!
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Figure 3.7. Job’s Plot for minocycline interaction with Zn2+ at a total concentration of 0.6 mM in NEM
bffer. Absorbance readings were taken at 330 nm for a series of ZnCl2 and minocycline mixtures of
varying Zn2+ molar fraction. The red dotted line marks the position of the minima which corresponds to a
Zn2+ molar fraction of 0.30. This molar fraction was then used to calculate the stoichiometric ratio of Zn2+
and minocycline complex, which was 0.43 Zn2+ bound per minocycline or a 2:1 MC:Zn2+ ratio.

The binding stoichiometries were determined as described above for tigecycline and minocycline
using absorbance readings at two different wavelengths for each antibiotic. Due to the weak
affinity of tetracycline for Zn2+ and the relatively low molar absorptivity of tetracycline and its
complex with Zn2+, the Job’s plots for tetracycline interaction with Zn2+ were plagued with
significant data scattering to the point that a clear minimum could not be identified for
experiments at 382 nm, but was identified for experiments at 349 nm. The Job’s method showed
that the stoichiometry in the tetracycline and Zn2+ complex was pH dependent: at pH 6.80 the n
value was 0.54 Zn2+ per tetracycline, corresponding to two tetracycline molecules binding to one
Zn2+, but at pH 7.50 the n value was 0.82 Zn2+ per tetracycline. These values do not agree well
with the results from the ITC study which showed that although binding was pH dependent, the n
value was 0.64 ± 0.08 Zn2+ per tetracycline at pH 6.80 and 0.515 ± 0.007 Zn2+ per tetracycline at
pH 7.50. Because tetracycline binding to Zn2+ is the weakest, the Job’s plots for this interaction
had the greatest variance, which may have resulted in slightly inaccurate stoichiometric values.

	
  

82	
  

	
  
A small uncertainty in the position of the minima in the Job’s plot translates into a much more
pronounced uncertainty in the molar ratio of the two components in the complex. The
stoichiometric ratios obtained from ITC were associated with less obvious uncertainty and
therefore should be trusted more than those from the Job’s method.
Similarly, the interactions of minocycline and tigecycline with Zn2+ were found to be pH
independent. At both pH 6.80 and pH 7.50, minocycline was found by Job’s plots to bind Zn2+ at
a stoichiometric ratio of 0.43 Zn2+ per minocycline, which corresponds approximately to 1:2
Zn2+:minocycline. This result agrees very well with the results from ITC with which minoccline
was found to bind Zn2+ with an n value of 0.43 ± 0.08 Zn2+ per minocycline at pH 6.80, and 0.450
± 0.008 Zn2+ per minocycline at pH 7.50. With its highest affinity for Zn2+ out of the three
antibiotics, minocycline yielded the highest quality UV-Vis data and therefore the most accurate
n value. Of the four UV-Vis experiments performed for tigecycline, three yielded Job’s plots that
gave n values of 0.54 Zn2+ per tigecycline while one gave an n value of 0.33 Zn2+ per tigecycline.
The average of the four experiments is 0.5 ± 0.1 Zn2+ per tigecycline, which corresponds to 1:2
Zn2+:tigecycline. These values for tigecycline from the Job’s plots did not agree as well with the
ITC results (n of 0.44 ± 0.04 and 0.39 ± 0.03 at pH 7.50 and pH 6.80, respectively) as the
minocycline data did. The weaker affinity of tigecycline than minocycline for Zn2+ contributed to
a somewhat higher uncertainty in data for tigecycline from the Job’s method.
Table 3.3. Stoichiometric Ratios for Tetracycline – Zn2+ interaction determined by Job’s Method based
on UV-Vis absorbance values. Total concentration is 0.6 mM.

pH
pH 6.8
pH 7.5

Analysis
wavelength (nm)
349
349

Zn2+:(TC+Zn2+)

n (Zn2+:TC)

0.35
0.45

0.54
0.82

Table 3.4. Stoichiometric Ratios for Minocycline – Zn2+ interaction determined by Job’s Method based
on UV-Vis absorbance values. Total concentration is 0.6 mM.

pH
pH 6.8
pH 7.5
pH 6.8
pH 7.5

	
  

Analysis
wavelength (nm)
330
330
349
349

Zn2+:(MC+Zn2+) n (Zn2+:MC)
0.30
0.30
0.30
0.30

0.43, (1:2)
0.43, (1:2)
0.43, (1:2)
0.43, (1:2)
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Table 3.5. Stoichiometric Ratios for Tigecycline – Zn2+ interaction determined by Job’s Method based on
UV-Vis absorbance values. Total concentration is 0.6 mM.

pH
pH 6.8
pH 7.5
pH 6.8
pH 7.5

Analysis wavelength
(nm)
330
330
349
349

Zn2+:(TgC+Zn2+)
0.35
0.25
0.35
0.35

n
(Zn2+:TgC)
0.54, (1:2)
0.33, (1:3)
0.54, (1:2)
0.54, (1:2)

The interaction of Zn2+ with tetracycline, minocycline and tigecycline was studied using
two different methods, ITC and Job’s method based on UV-Vis absorbance readings, to
determine different physical parameters for the interaction. ITC results indicate that minocycline
binds Zn2+ with n values of 0.450 ± 0.008 and 0.43 ± 0.08 at pH 7.50 and pH 6.80, respectively.
ITC results showed tigecycline binds Zn2+ with n values of 0.4 ± 0.1 and 0.39 ± 0.03 at pH 7.50
and pH 6.80, respectively. ITC results demonstrated that tetracycline binds Zn2+ in a pH
dependent manner, with n values of 0.515 ± 0.007 and 0.64 ± 0.08 at pH 7.50 and pH 6.80,
respectively. Binding of tetracycline to Zn2+ results in an entropic gain at both pH 6.80 and pH
7.50. The n values determined for tetracycline from Job’s method did not agree well with the
ITC data. The greatest discrepancy was for tetracycline interacting with Zn2+ at pH 7.50, for
which the two methods gave n values with a 46% difference. This can be attributed to
tetracycline’s weak affinity for Zn2+ thus greater uncertainty in identifying the position of the
minima on the Job’s plots. Minocycline had the greatest affinity for Zn2+ and tetracycline had the
weakest affinity for Zn2+. Job’s method gave more robust results when affinity was strong, as it
makes it more straightforward to identify the maxima or minima on the plot. When affinity of the
interaction is weaker, there is greater error in the data points, particularly the data points
corresponding to the presence of less of the light-absorbing species (the tetracyclines) and more
of the non-absorbing species (Zn2+). Attempts at addressing this issue included trying a greater
total concentration, but for this project when concentration was increased above 0.6 mM the
absorbance exceeded the maximum absorbance that the instrument is able to accurately measure.
3.4 UV-Vis studies of three members of the tetracycline family interacting with Ca2+
Isothermal titration calorimetry is a useful technique to acquire the thermodynamic and
stoichiometric parameters of an interaction, but it is also often necessary to confirm results with a
different method, especially when the results from one method are perplexing. A study
performed in the Jin lab that investigated the interaction of three members of the tetracycline
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family – tetracycline, minocycline, and tigecycline – with Ca2+ yielded perplexing stoichiometric
ratios for the interaction.39 A UV-Vis study using Job’s Method was employed in this work to
confirm the stoichiometric ratio determined by ITC for the Ca2+ as well as Zn2+ binding of the
three tetracyclines. Although the ITC study for the Ca2+ interaction was motivated by the need to
understand the bioavailability of the tetracyclines in the gastrointestinal tract where Ca2+ is
abundant, findings from the Ca2+ binding studies are also relevant for the design of future
chemically modified tetracyclines as potential MMP inhibitors since MMPs are inhibited by
molecules that bind structural Ca2+ and Zn2+.
The ITC study revealed that the three tetracyclines do not bind Ca2+ in the same
stoichiometric ratios (Table 3.6). Unlike for minocycline (MC) and tigecycline (TgC), the Ca2+
complexes for tetracycline (TC) were pH dependent. In NEM buffer the complex had a 1:3
Ca2+:TC stoichiometric ratio, while in Tris buffer, the complex had a 1:1 Ca2+:TC stoichiometric
ratio. The compositions of the Ca2+ complexes for minocycline and tigecycline were pH
independent: a 1:3 Ca2+:MC stoichiometric ratio was obtained for minocycline in both NEM
buffer and Tris buffer; a 2:3 Ca2+:TgC stoichiometric ratio was found for tigecycline at both pH
values.
Table 3.6. Stoichiometric Ratios for Antibiotic – Ca2+ determined by ITC at two different pH values39

Compound
TC
MC
TgC

n (Ca2+/antibiotic)
pH 6.80
0.347 ± 0.007
0.369 ± 0.002
0.69 ± 0.07

n (Ca2+/antibiotic)
pH 7.50
0.94 ± 0.01
0.38 ± 0.08
0.65 ± 0.02

*Experiments done in NEM buffer pH 6.80 or Tris buffer pH 7.50

The Job’s Method involved monitoring the interactions via absorbance readings at a
given wavelength for a series of Ca2+ and antibiotic mixtures at constant total concentration,
ionic strength, and pH. For each experiment, three replicates of each sample were prepared and
absorbance readings were taken using a microplate reader. The three replicate measurements
were analyzed and averaged. A value proportional to the concentration of antibiotic-Ca2+
complex formed was determined using equation (1), in which AB represents free antibiotic. The
concentration of the complex formed at a given molar fraction has been shown to be proportional
to the observed absorbance for the mixture of metal ion and antibiotic (Aobs) minus the
absorbance of the free antibiotic which is the product of the path length (b), molar absorptivity
(ε) and concentration of the free antibiotic in each sample [AB]:
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complex ∝ (A!"# − AB ∗ b ∗ ε )

(1)

The above term proportional to the concentration of complex was plotted as a function of the
molar fraction of Ca2+ (i.e. Ca!! /( Ca!! + AB )) and the position of the maxima or minima
on the Job’s plot was used to determine the stoichiometric ratio for each interaction. A
representative Job’s plot for the study of tigecycline and Ca2+ binding in NEM buffer is shown
below (Figure 3.8). The molar fraction of Ca2+ corresponding to the minima was identified and
used to calculate the stoichiometric ratio of Ca2+ to tigecycline in the complex using Equation
(2).
!"#$  !"#$%&'(  !!!

Stoichiometric  molar  ratio = !!!"#$  !"#$%&'(  !!!

(2)

Figure 3.8. Job’s Plot for 0.6 mM tigecycline and 0.6 mM Ca2+ in NEM Buffer at 330 nm. The red dotted
line indicates the location of the minima and corresponding molar fraction of Ca2+ for the interaction. The
molar fraction of Ca2+ is then used to calculate the stoichiometric ratio of the two components in the
complex.

Each antibiotic-Ca2+ interaction was investigated in both NEM buffer pH 6.80 and Tris buffer pH
7.50. Absorbance readings at the wavelengths of maximum absorbance for the free antibiotic and
antibiotic-Ca2+ complex were analyzed using Job’s method. Results indicate that tetracycline
demonstrated a pH-dependent binding mode just as was revealed in the ITC studies. At pH 6.8,
tetracycline was determined to bind Ca2+ in a stoichiometric ratio of 0.33 Ca2+ per TC (1 Ca2+: 3
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TC), which matches the stoichiometric ratio of 0.347 ± 0.007 Ca2+ per TC from ITC. At pH 7.5,
the stoichiometric ratio was found to be close to 1:1, just as was observed in the ITC study with
an n value of 0.94 ± 0.01. The minocycline UV-Vis results also agreed well with the ITC data.
Minocycline was found to bind Ca2+ in a pH-independent manner with a stoichiometric ratio of
0.43 Ca2+:MC which agrees well with the 0.369 ± 0.002 and 0.38 ± 0.08 Ca2+:MC from ITC. The
tigecycline UV-Vis data was less consistent with the ITC results than the other two tetracyclines.
At pH 6.8, n values from individual experiments ranging from 0.67-1 were obtained, whereas at
pH 7.5, n values from individual experiments ranged from 0.43-0.67. In the ITC studies,
tigecycline did not demonstrate pH dependent binding and n values were 0.69 ± 0.07 and 0.65 ±
0.02 at pH 6.80 and pH 7.50, respectively. The stoichiometric ratios determined from the Job’s
plots have a higher uncertainty than those from ITC. Although associated with a higher standard
deviation, the average of the n values of 0.8 ± 0.2 at pH 6.80 and 0.6 ± 0.1 from the UV-Vis
study using the Job’s plot, does match reasonably well with the ITC result and confirms that the
stoichiometric ratio for tigecycline with Ca2+ differs from those of minocycline or tetracycline
with Ca2+. Overall, the ITC data should be trusted more and the UV-Vis data is merely a
complement to the ITC results.
Table 3.7. Stoichiometric Ratios for Tetracycline – Ca2+ interaction determined by Job’s Method.
Analysis
Buffer, pH
Ca2+:(TC+Ca2+)
n (Ca2+:TC)
wavelength (nm)
NEM, 6.8
358
0.25
0.33, (1:3)
NEM, 6.8
349
0.25
0.33, (1:3)
NEM, 6.8
358
0.25
0.33, (1:3)
NEM, 6.8
349
0.25
0.33, (1:3)
Tris, 7.5
382
0.55
1.2, (1:1)
Tris, 7.5
382
0.6
1.5, (1:1)
*Total concentration is 0.6 mM for all analyses.

Table 3.8. Stoichiometric Ratios for Minocycline – Ca2+ interaction determined by Job’s Method.
Buffer, pH
[MC] (mM)
[Ca2+] (mM)
Ca2+:(MC+Ca2+)
n (Ca2+:MC)
NEM, pH 6.8
0.6
0.6
0.3
0.43 (1:2)
NEM, pH 6.8
0.3
0.3
0.3
0.43 (1:2)
Tris, pH 7.5
0.6
0.6
0.35
0.54 (1:2)
Tris, pH 7.5
0.3
0.3
0.3
0.43 (1:2)
* All analyses were done at a wavelength of 349 nm.
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Table 3.9. Stoichiometric Ratios for Tigecycline – Ca2+ interaction determined by Job’s Method
Analysis
Buffer, pH
[TgC] (mM)
[Ca2+] (mM)
Ca2+:(TgC+Ca2+) n (Ca2+:TgC)
wavelength (nm)
NEM, pH 6.8
0.6
0.6
330
0.5
1.0 (1:1)
NEM, pH 6.8
0.6
0.6
349
0.45
0.82 (1:1)
NEM, pH 6.8
0.3
0.3
349
0.4
0.67 (2:3)
Tris, pH 7.5
0.6
0.6
330
0.4
0.67 (2:3)
Tris, pH 7.5
0.6
0.6
349
0.40
0.67 (2:3)
Tris, pH 7.5
0.3
0.3
349
0.3
0.43 (1:2)

The Job’s plots of Ca2+ interacting with tetracycline, minocycline, and tigecycline were
performed as a means of confirming the stoichiometric ratios obtained from the ITC studies.
Though the Job’s method provides a less precise stoichiometric ratio, it is a valuable complement
to the ITC results. It did confirm that the 2 Ca2+ per 3 TgC stoichiometric ratio, though puzzling,
was occurring. The stoichiometric ratio for the interaction of tetracycline with Ca2+ was found to
be pH-dependent using both methods with a ratio of 0.33 Ca2+:TC at pH 6.80 and essentially 1
Ca2+: 1 TC at pH 7.50. The interaction of minocycline with Ca2+ was determined to be pHindependent using both methods with a ratio of 0.43 Ca2+:TC. The interaction of tigecycline with
Ca2+ was also determined as pH-independent using both methods, but the data varied more for
tigecycline than the other two antibiotics. For pH 7.50, the ratio average was slightly below 0.67
and for pH 6.80 the ratio was slightly above 0.67; however, overall the interaction between
tigeycline and Ca2+ was found to be 0.67 Ca2+:TC regardless of pH. Job’s method proves to be a
good complement to the stoichiometric data obtained from ITC for this study.

	
  

88	
  

	
  
Chapter 4. Experimental Methods
4.1 Synthesis of (N-(2-(1-methylimidazolyl)methyl)iminodiacetic acid) DA2Im
Synthesis of N-(2-(1-methylimidazolyl)methyl)iminodiacetic acid (DA2Im) was
accomplished in two steps.26 Diethyl iminodiacetate (1.80 mL, 10.3 mmol) and 1-methyl-2imidazolecarboaldehyde (1.031 g, 9.4 mmol) were combined in DCE (30 mL). A reductive
amination was achieved with sodium triacetoxyborohydride (2.976 g, 14.0 mmol) under N2.40 The
reaction was allowed to proceed overnight under stirring. The reaction was quenched with
saturated sodium bicarbonate, extracted three times with ethyl acetate (40 mL), and dried with
magnesium sulfate. The product was purified by column chromatography (silica gel, 100% ethyl
acetate) to yield a light yellow oil. The oil was dissolved in 25 mL of 2 N HCl and refluxed
overnight. The product was concentrated in vacuo and dried in a vacuum oven to remove any
residual water. Removal of solvent yielded 1.172 g of a flaky, off-white solid (38% yield). 1H
NMR (300 MHz, D2O) δ = 7.25-7.32 (d, 2H), 4.2-4.4 (s, 2H), 3.8-3.9 (s, 3H), 3.6-3.8 (s, 4H).
In an effort to avoid generation of chlorinated waste, the synthesis was attempted using
ethyl acetate as the solvent rather than DCE. This synthesis was unsuccessful as various side
products were generated.
4.2 Synthesis of 2-benzyl-amino-naphthoquinone (NQN-1)
NQN-1 (2-benzyl-amino-napthoquinone) was synthesized in two steps based on the
synthesis by Inks et al.41 Sodium azide (0.6825 g, 10.5 mmol) was dissolved in water to form a 6
M solution, and then acidified with glacial acetic acid to obtain a 5 M sodium azide solution
(Caution: azides are toxic and explosive). The sodium azide solution was added to a solution of
0.3 M 1,4-napthoquinone (0.5230 g, 3.31 mmol) in 4:1 THF:H2O and stirred at room temperature
for one week. The reaction was concentrated, dissolved in ethyl acetate and washed sequentially
with 1 M NaOH and brine. The organic phase was dried with Na2SO4 and concentrated in vacuo
to yield the reddish brown 2-amino-1,4-napthoquinone product (0.3348 g, 58% yield). The 1H
NMR matched the literature data and showed that the product from step one was relatively pure
thus no column chromatography was performed.41
The 2-amino-1,4-napthoquinone product (0.2485 g, 1.43 mmol) and sodium hydride
(0.1155 g, 4.8) were dissolved in dry THF under N2 to form a 1 M solution. Benzoyl chloride
(0.167 mL, 1.44 mmol) was added and the reaction was stirred for nine days. The reaction was
quenched with water and extracted three times with DCM. The organic extracts were combined
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and washed sequentially with 1 M NaOH, 1 M HCl, and brine. The organic phase was dried with
Na2SO4 and concentrated in vacuo. The resulting powder was purified by column
chromatography (silica gel, 10/50% v/v ethyl acetate/hexane) to yield an orange powder of N(1,4-dioxo-1,4-dihydronapthalen-2-yl)benzamide (0.1198 g, 30% yield). 1H NMR (300 MHz,
CDCl3) δ = 9.2 (s, 1H), 8.14-8.22 (m, 2 H), 8.06 (s, 1H), 7.93-8.01 (m, 2 H), 7.73-7.88 (m, 2 H),
7.62-7.69 (m, 1H), 7.53-7.62 (m, 2H).
4.3 Isothermal Titration Calorimetry
ITC experiments were performed on a MicroCal VP-ITC unit (GE Healthcare) at 25 °C.
Prior to setting up each experiment, the injection syringe and calorimeter reaction cell were
allowed to soak in detergent (10% Contrad detergent, 0.1 M EDTA). Milli-Q water was then
used to rinse the syringe (30 mL) and the reaction and reference cells exhaustively, and the
syringe was dried with air. Before sample loading, sample solutions prepared in buffer were
degassed using a ThermoVac degassing station (Malvern Instruments). Samples in the 60:40
methanol:buffer mixture or acetonitrile were not degassed to prevent differential evaporation of
organic versus aqueous solvent, thus significantly changed solution composition. The reference
cell of the calorimeter was always filled with the same solvent system that was used to prepare
the samples.
Analysis of calorimetric data was performed using Origin 7.2 software (OriginLab,
Northhampton, MA) that was packaged with the instrument. The baseline for the raw data
(μWatt versus second) was manually corrected. The integration of the area under each peak
yields the heat associated with each injection, which is automatically normalized per mole of
titrant. This normalized heat as a function of titrant:titrate molar ratio gives rise to the binding
isotherm. The heat generated or absorbed during the binding interaction is directly related to the
fraction of ligand bound. If a significant control heat for the dilution of the titrant was observed,
it was subtracted from the binding isotherm. The binding isotherm was then fit to either a oneset-of-sites or two-sets-of-sites binding model provided by the manufacturer in the Origin 7.2
software (OriginLab, Northhampton, MA). The fit was iterated to achieve the lowest Chisquared value. In some instances it was necessary to subtract a constant value corresponding to
the plateau heat of a binding isotherm which is conventionally thought to be a better control than
a control experiment of injecting the titrant into a solution minus the titrate (often the buffer). A
nonlinear least square approach (Levenberg-Marquardt algorithm) is then used to determine the
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thermodynamic parameters for the interaction studied: n, Ka, ΔH°, and ΔS°. The equilibrium
association constant was used to calculate ΔG° for the reaction (Equation 3).
Δ𝐺 ∘ = −RT ∗ ln(𝐾! )

(3)

The ΔH° determined from curve fitting and the calculated ΔG° values were used to calculate
TΔS° using Equation (4).
△ 𝐺 ∘ =△ 𝐻∘ − T △ 𝑆 ∘ 	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  (4)
The dissociation constant (Kd) was calculated from the Ka using Equation (5).
!

𝐾! = !

!

(5)

The parameters obtained from replicate runs were averaged and error propagation was performed
for the parameters of each interaction studied.
4.3.1 Zn2+ with N-(2-(1-methylimidazolyl)methyl)iminodiacetic acid (DA2Im),
nitrilotriacetic acid (NTA), bis(2-picolyl)amine (BPA), tris(2-pyridylmethyl)amine (TPA),
and tris(2-aminoethyl)amine (Tren)
DA2Im, NTA, BPA, TPA, TREN titration experiments with Zn2+ were performed in two
different solvent conditions: 50 mM NEM buffer (0.150 M NaCl, pH 6.80) or 60:40 (by volume)
mixture of MeOH: 50 mM NEM buffer (0.150 M NaCl) at pH 6.80, which will from here on out
be referred to as NEM buffer or MeOH:buffer mixture, respectively. Some ligands were only
soluble in one solvent system and thus were not able to be studied in both solvent systems;
specifically, NTA was insoluble in the MeOH:buffer mixture and TPA was insoluble in NEM
buffer. The NEM buffer was prepared in a 1 L Nalgene bottle using Milli-Q water (≥18 MΩ,
Milli-Q integral water purification system, Millipore) with 0.150 M NaCl and adjusted to pH
6.80. The MeOH:buffer mixture was prepared by combining 30 mL of MeOH with 20 mL of 50
mM NEM buffer (0.15 M NaCl, pH 6.80) in a 50 mL conical tube and the pH was readjusted to
within ± 0.02 of pH 6.80 by adding approximately 90 μL of 1 M NaOH. Solutions of NTA,
DA2Im, BPA, TPA, TREN and zinc chloride were prepared gravimetrically and the final
solution was adjusted to within ± 0.02 units of the desired pH.
NTA and DA2Im both contain multiple carboxyl groups that could lead to dimerization
in the syringe; thus, studies with these ligands were conducted by titrating Zn2+ into the ligand
solution. Studies with TREN, TPA and BPA are performed with ligand as the titrant and Zn2+ as
the titrate contained in the reaction cell. The reference cell was filled with the corresponding
solvent system used to prepare the Zn2+ and ligand solutions. The titrant was titrated into the
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reaction cell in 10 μL aliquots over 20 seconds for a total of 28 injections. The syringe was set to
stir at 307 rpm for the duration of the experiment. Between each injection, 360 seconds elapse to
ensure adequate time for the signal to return to the baseline. A minimum of two experiments was
conducted for each ligand to ensure reproducibility.
Table 4.1. Concentrations of Titrant and Titrate for Ligand-Zn2+ Studies
Titrant
Zn2+
Zn2+
Zn2+
TPA
BPA
BPA
TREN
TREN

Titrant Concentration
(mM)
0.15
0.3
0.3
3
3
3
10
10

Titrate

Titrate Concentration (mM)

Solvent System

DA2Im
NTA
TPA
Zn2+
Zn2+
Zn2+
Zn2+
Zn2+

0.03
0.06
0.03
0.3
0.3
0.3
1
1

Buffer
Buffer
MeOH:Buffer
MeOH:Buffer
Buffer
MeOH:Buffer
Buffer
MeOH:Buffer

*Buffer corresponds to 50 mM NEM Buffer (0.150 M NaCl, pH 6.80). MeOH:Buffer corresponds to 60:40 (by
volume) MeOH: 50 mM NEM Buffer (0.15 M NaCl) mixture at pH 6.80

Data analysis was performed using Origin 7.2 software (OriginLab, Northhampton, MA)
as described above. The resulting binding isotherms for studies of DA2Im, NTA, TPA, and
TREN with Zn2+ were fit to an iterative, one-set-of-site binding model (MicroCal, LLC). The
isotherms for the BPA interaction with Zn2+ were fit with an iterative, two-sets-of-sites binding
model (MicroCal LLC). The binding parameters of the replicate experiments were averaged and
error propagation was performed.
4.3.2 Potential HDAC structural Mimetics with suberoylanilide hydroxamic acid (SAHA),
acetohydroxamic acid (AHA), 8-Hydroxyquinoline, and 2-benzyl-amino-naphthoquinone
(NQN-1)
AHA experiments were performed in two different solvent conditions: 50 mM NEM
buffer (0.1 M NaCl, pH 6.80) or 60% MeOH, 40% 50 mM NEM buffer (0.1 M NaCl, pH 6.80).
8-hydroxyquinoline was insoluble in NEM Buffer thus was only studied in the MeOH:buffer
mixture. Experiments with SAHA were unsuccessful, as its weak affinity with the structural
mimetics required higher concentrations of SAHA for the ITC study than allowed by its
solubility. NQN-1 interaction with the HDAC structural mimetic could not be studied using ITC
as NQN-1 was not soluble at concentrations necessary for ITC. AHA and 8-hydroxyquinoline
solutions were prepared gravimetrically and the final pH was adjusted to within ± 0.02 units of
the desired pH. Solutions of BPA, Tren, TPA and ZnCl2 were prepared gravimetrically at
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concentrations greater than what is desired for the final concentration of ligand-Zn2+ complex.
The solution of ligand and Zn2+ were mixed in the appropriate volumes to yield the desired final
concentration and the solution was also adjusted to within ± 0.02 units of the desired pH. For
example, to make 3 mL solution of a BPA-Zn2+ complex at a final concentration of 1 mM for
both Zn2+ and BPA, 1.5 mL of a 2 mM ZnCl2 solution was mixed with 1.5 mL of a 2 mM BPA
solution.
Experiments were performed by titrating a solution of inhibitor into a solution of the
ligand-Zn2+ complex as an HDAC structural mimetic. Experiments with 8-hydroxyquinoline as
an inhibitor were done in 60:40 (by volume) mixture of MeOH: 50 mM NEM buffer (0.150 M
NaCl) at pH 6.80 by injecting 10 mM 8-hydroxyquinoline into the following ligand and ZnCl2
mixtures in their specific molar ratios indicated: 1 BPA: 1 Zn2+, 1.11 BPA: 1 Zn2+, 1.5 BPA: 1
Zn2+, 2 BPA: 1 Zn2+, 1.11 TPA: 1 Zn2+, and 1.11 TREN: 1 Zn2+. Experiments with AHA as
inhibitor were performed in both solvent systems by injecting 50 mM AHA into a solution
containing 5 mM ZnCl2 and 5 mM BPA (at 1:1 BPA:Zn2+ molar ratio). Due to large heat for the
early injections, the titrant was titrated into the reaction cell in 8 μL aliquots over 20 seconds for
a total of 35 injections. Between each injection, 240 seconds elapse to ensure adequate time for
the signal to return to the baseline. A minimum of two experiments was conducted for each
ligand to ensure reproducibility.
Table 4.2. Concentrations of Titrant and Titrate for Ligand-Zn2+ Studies
Titrant
AHA
AHA
8-HQ
8-HQ
8-HQ
8-HQ
8-HQ
8-HQ

Titrant Concentration
(mM)
50
50
10
10
10
10
10
10

Titrate
BPA:Zn2+
BPA:Zn2+
BPA:Zn2+
BPA:Zn2+
BPA:Zn2+
BPA:Zn2+
Tren:Zn2+
TPA:Zn2+

Titrate Concentration
(mM)
5:5
5:5
1:1
1.11:1
1.5:1
2:1
1.11:1
1.11:1

Solvent System
Buffer
MeOH:Buffer
MeOH:Buffer
MeOH:Buffer
Buffer
MeOH:Buffer
Buffer
MeOH:Buffer

*Buffer corresponds to 50 mM NEM Buffer (0.150 M NaCl, pH 6.80). MeOH:Buffer corresponds to 60:40 (by
volume) MeOH: 50 mM NEM Buffer (0.15 M NaCl) mixture at pH 6.80

Data analysis was performed using Origin 7.2 software (OriginLab, Northhampton, MA)
as described above. The resulting binding isotherms were fitted with an iterative, one-set-of-site
binding model (MicroCal, LLC). The binding parameters of the replicate experiments were
averaged and error propagation was performed.
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4.3.3 Zn2+ with tetracycline, minocycline, and tigecycline
Tetracycline hydrochloride (TC), minocycline hydrochloride (MC), tigecycline (TgC),
and anhydrous zinc chloride were purchased from commercial sources and used as received. All
TC, MC, TgC titration experiments with Zn2+ were conducted in either 50 mM NEM buffer (0.15
M NaCl, pH 6.80) or 50 mM Tris Buffer (0.10 M NaCl, pH 7.50). The buffers were prepared in
1 L Nalgene bottles using Milli-Q water (≥18 MΩ, Milli-Q integral water purification system,
Millipore). TC, MC, and TgC stock solutions were made fresh for each use as they are prone to
oxidation and degradation in aqueous solution. Solutions of TC, MC, TgC, and zinc chloride
were prepared gravimetrically and the final pH was adjusted to within ± 0.02 units of the desired
pH.
In all experiments, a 5.0 mM zinc chloride solution was loaded into the syringe as the
titrant to be injected into a 0.5 mM solution of antibiotic (as a titrate) contained in the reaction
cell (Table 4.1). The reference cell was filled with buffer. The zinc solution was titrated into the
reaction cell in 10 μL aliquots over 20 seconds for a total of 28 injections. The syringe was set to
stir at 307 rpm for the duration of the experiment. Injections were spaced 360 seconds apart to
allow time for the signal to return to the baseline. A minimum of two experiments were
conducted for each antibiotic to ensure reproducibility.
Data analysis was performed using Origin 7.2 software (OriginLab, Northhampton, MA)
as described above. The isotherm from a control experiment – which consisted of injection of
zinc chloride into NEM buffer – was subtracted from each experimental zinc-antibiotic isotherm
to eliminate heat associated with processes not involved in the zinc-antibiotic interaction. The
resulting isotherm was then fitted with a one-set-of-site binding model (MicroCal, LLC). The
binding parameters of the replicate experiments were averaged and error propagation was
performed.
4.4 UV-Vis Studies of three members of the tetracyclines with Zn2+ and Ca2+
Tetracycline hydrochloride (TC), minocycline hydrochloride (MC), tigecycline (TgC),
calcium chloride dihydrate, and anhydrous zinc chloride were purchased from commercial
sources and used as received. Tetracycline, minocycline, and tigecycline stock solutions were
made fresh for each use. All measurements were performed in a 96 well plate in either 50 mM
NEM buffer (0.150 M NaCl, pH 6.8) or 50 mM Tris buffer (0.100 M NaCl, pH 7.5) on a
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Synergy H1 Hybrid microplate reader (BioTek). Buffers were prepared using Milli-Q water (≥18
MΩ, Milli-Q integral water purification system, Millipore). Stock solutions of the three
tetracyclines were prepared at 3 mM or 4mM each time, then diluted to the desired
concentration. The calcium chloride and zinc chloride stock solutions were prepared at 2 mM,
parafilmed and stored, and dilutions were made each time from the stock solutions. The pH of
each stock solution was adjusted to within ± 0.02 units of the desired pH before samples were
prepared for measurement.
The UV-Vis studies were done using Job’s Method; thus it was critical that the total
concentration of the two interacting species – antibiotic and metal ion – remain constant for all
samples in the experiment while each species’ mole fraction was varied. The details of sample
preparation for a typical experiment are presented in Table 4.3. The pH and ionic strength were
kept constant by doing the experiments in buffer. For each experiment, a 5 mL stock solution of
each species was prepared. Each sample was pipetted into the 96 well plate in varying volumetric
ratios, always totaling 100 μL. Three replicates were prepared of each sample and the microplate
reader was set to take and average eight measurements of each sample. After both species were
added, each sample was mixed well by pipetting the solution up and re-dispensing it a minimum
of three times.
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Table 4.3. Sample preparation for a typical UV-Vis study using Job’s Method

Sample
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Replicate Wells
A1, A2, A3
A4, A5, A6
A7, A8, A9
A10, A11, A12
B1, B2, B3
B4, B5, B6
B7, B8, B9
B10, B11, B12
C1, C2, C3
C4, C5, C6
C7, C8, C9
C10, C11, C12
D1, D2, D3
D4, D5, D6
D7, D8, D9
D10, D11, D12
E1, E2, E3
E4, E5, E6
E7, E8, E9
E10, E11, E12
F1, F2, F3
F4, F5, F6

Volume of M2+
(μL)
0
2.5
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100

Volume of
antibiotic (μL)
0
97.5
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0

The absorbance measurements were taken at a pre-determined ideal wavelength to follow
the complex formation. The proper wavelength for the absorbance measurement was determined
by taking an absorption scan spectrum of pure antibiotic solution and also a fully complexed
antibiotic-metal ion mixture (achieved by pipetting 10 μL of 0.5 M metal ion solution into 1 mL
of antibiotic) on a Nanodrop 1000 spectrophotometer (ThermoScientific). The λmax for the free
antibiotic species and the fully formed complex were the wavelengths selected for the UV-Vis
measurements for Job’s method.
Analysis of the data was performed using Origin (OriginLab, Northhampton, MA). The
absorbance measurement of the calcium solution was considered the blank and subtracted from
all absorbance measurements. The molar absorptivity for the antibiotic studied was calculated at
the wavelength used for analysis for each experiment based on the absorbance measurement
recorded and concentration of the antibiotic sample using Beer’s law in which absorbance (A) is
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the product of pathlength (b), concentration (c) and the molar absorptivity of the light absorbing
species (ε) (Equation 6).
A=b∗c∗ε

(6)

The molar absorptivity (ε), concentration of antibiotic in each sample [AB], absorbance
measurement (Aobs) and path length (b) were used to determine a value proportional to the
amount of antibiotic-M2+ complex formed (where antibiotic stands for TC, MC, or TgC and M2+
indicates Ca2+ or Zn2+) using equation (1):
complex ∝ A!"# − AB ∗ b ∗ ε

(1)

Each experiment yielded three replicate measurements for each sample. These three
replicates were analyzed using equation (1) and the determined concentrations of complex for
the replicates were averaged for each sample and the standard deviation was calculated. The
average concentration was plotted as a function of the molar fraction of the divalent metal ion
studied. This plot yielded the typical Job’s plot in which the maximum or minimum on the plot
(Molar fraction of metal ion, Equation 7) correlates to the stoichiometry of the interaction.
Molar  Fraction  M !! =

!!!
!!! ! !"

(7)

The data points corresponding to lower molar fractions of Ca2+ in the Job’s plot typically were
associated with larger uncertainty and the data trend was therefore less robust. The molar
fractions corresponding to the maximum or minimum were used to calculate the stoichiometric
molar ratio of the interaction between antibiotic and metal ion using Equation (2).
!"#$  !"#$%&'(  !!!

  Stoichiometric  molar  ratio = !!!"#$  !"#$%&'(  !!!

(2)

Value of the molar fraction of metal determined from the maxima or minima and the calculated
stoichiometric ratios are the values presented in Chapter 3.
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4.5 Attempts to Crystallize SAHA with Zinc(II)
Obtaining a crystal structure of the HDAC inhibitor, SAHA, with Zn(II) can offer
additional information about the inhibitor-Zn2+ interaction. SAHA has been crystallized with
various metals, but a crystal structure of SAHA with Zn2+, though attempted numerous times, has
never been achieved. Attempts at crystallizing SAHA with Zn(II) are summarized in the table
below, none of which yielded crystals suitable to be sent off for analysis. All crystallization was
attempted on a 100 mg SAHA scale with zinc acetylacetonate.
Table 4.4. Summary of attempted approaches for crystallizing SAHA with Zn(II)

	
  

Ratio of SAHA:Zn(II)

Solvent

Method

2:1

DCM

Slow evaporation of solvent

2:1

2:1 MeOH:H2O

Slow evaporation of solvent

2:1

DMSO

Vapor diffuse in THF

2:1

DMSO

Vapor diffuse in acetone

2:1

DMSO

Vapor diffuse in acetonitrile

2:1

DMSO

Vapor diffuse in DCM
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Appendices: Job’s Plots
A. Job’s Plots for Tetracycline and Ca2+ Interaction

Figure A1. Job’s Plot for 0.6 mM TC and 0.6 mM Ca2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C

Figure A2. Job’s Plot for 0.6 mM TC and 0.6 mM Ca2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C
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Figure A3. Job’s Plot for 0.6 mM TC and 0.6 mM Ca2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 358
nm and 25 °C

Figure A4. Job’s Plot for 0.6 mM TC and 0.6 mM Ca2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 382 nm
and 25 °C
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Figure A5. Job’s Plot for 0.6 mM TC and 0.6 mM Ca2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 382 nm
and 25 °C

B. Job’s Plots for Minocycline and Ca2+ Interaction

Figure B1. Job’s Plot for 0.6 mM MC and 0.6 mM Ca2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C
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Figure B2. Job’s Plot for 0.6 mM MC and 0.6 mM Ca2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 349 nm
and 25 °C

Figure B3. Job’s Plot for 0.3 mM MC and 0.3 mM Ca2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C

	
  

106	
  

	
  

Figure B4. Job’s Plot for 0.3 mM MC and 0.3 mM Ca2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 349 nm
and 25 °C

C. Job’s Plots for Tigecycline and Ca2+ Interaction

Figure C1. Job’s Plot for 0.6 mM TgC and 0.6 mM Ca2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C
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Figure C2. Job’s Plot for 0.6 mM TgC and 0.6 mM Ca2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 330
nm and 25 °C

Figure C3. Job’s Plot for 0.6 mM TgC and 0.6 mM Ca2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 349 nm
and 25 °C
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Figure C4. Job’s Plot for 0.6 mM TgC and 0.6 mM Ca2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 330 nm
and 25 °C

Figure C5. Job’s Plot for 0.3 mM TgC and 0.3 mM Ca2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C
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Figure C6. Job’s Plot for 0.3 mM TgC and 0.3 mM Ca2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 349 nm
and 25 °C

D. Job’s Plots for Tetracycline and Zn2+ Interaction

Figure D1. Job’s Plot for 0.6 mM TC and 0.6 mM Zn2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C
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Figure D2. Job’s Plot for 0.6 mM TC and 0.6 mM Zn2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 349 nm
and 25 °C

E. Job’s Plots for Minocycline and Zn2+ Interaction

Figure E1. Job’s Plot for 0.6 mM MC and 0.6 mM Zn2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 330
nm and 25 °C
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Figure E2. Job’s Plot for 0.6 mM MC and 0.6 mM Zn2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 330 nm
and 25 °C

Figure E3. Job’s Plot for 0.6 mM MC and 0.6 mM Zn2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C
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Figure E4. Job’s Plot for 0.6 mM MC and 0.6 mM Zn2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 349 nm
and 25 °C

F. Job’s Plots for Tigecycline and Zn2+ Interaction

Figure F1. Job’s Plot for 0.6 mM TgC and 0.6 mM Zn2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 330
nm and 25 °C
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Figure F2. Job’s Plot for 0.6 mM TgC and 0.6 mM Zn2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 330 nm
and 25 °C

Figure F3. Job’s Plot for 0.6 mM TgC and 0.6 mM Zn2+, 50 mM NEM Buffer (0.15 M, pH 6.80), at 349
nm and 25 °C
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Figure F4. Job’s Plot for 0.6 mM TgC and 0.6 mM Zn2+, 50 mM Tris Buffer (0.1 M, pH 7.50), at 349 nm
and 25 °C
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